1. Biochemistry and Chemical Biology
  2. Genetics and Genomics

Manganese is a physiologically relevant TORC1 activator in yeast and mammals

  1. Raffaele Nicastro
  2. Hélène Gaillard
  3. Laura Zarzuela
  4. Marie-Pierre Péli-Gulli
  5. Elisabet Fernández-García
  6. Mercedes Tomé
  7. Néstor García-Rodríguez
  8. Raúl V Durán
  9. Claudio De Virgilio  Is a corresponding author
  10. Ralf Erik Wellinger  Is a corresponding author
  1. University of Fribourg, Department of Biology, Switzerland
  2. Centro Andaluz de Biología Molecular y Medicina Regenerativa - CABIMER, Consejo Superior de Investigaciones Científicas, Universidad de Sevilla, Spain
  3. Departamento de Genética, Facultad de Biología, Universidad de Sevilla, Spain
https://doi.org/10.7554/eLife.80497
Share this article
Cite this article
  1. Raffaele Nicastro
  2. Hélène Gaillard
  3. Laura Zarzuela
  4. Marie-Pierre Péli-Gulli
  5. Elisabet Fernández-García
  6. Mercedes Tomé
  7. Néstor García-Rodríguez
  8. Raúl V Durán
  9. Claudio De Virgilio
  10. Ralf Erik Wellinger
(2022)
Manganese is a physiologically relevant TORC1 activator in yeast and mammals
eLife 11:e80497.
https://doi.org/10.7554/eLife.80497
  2. Download BibTeX
  3. Download .RIS

Abstract

The essential biometal manganese (Mn) serves as a cofactor for several enzymes that are crucial for the prevention of human diseases. Whether intracellular Mn levels may be sensed and modulate intracellular signaling events has so far remained largely unexplored. The highly conserved target of rapamycin complex 1 (TORC1, mTORC1 in mammals) protein kinase requires divalent metal cofactors such as magnesium (Mg2+) to phosphorylate effectors as part of a homeostatic process that coordinates cell growth and metabolism with nutrient and/or growth factor availability. Here, our genetic approaches reveal that TORC1 activity is stimulated in vivo by elevated cytoplasmic Mn levels, which can be induced by loss of the Golgi-resident Mn2+ transporter Pmr1 and which depend on the natural resistance-associated macrophage protein (NRAMP) metal ion transporters Smf1 and Smf2. Accordingly, genetic interventions that increase cytoplasmic Mn2+ levels antagonize the effects of rapamycin in triggering autophagy, mitophagy, and Rtg1-Rtg3-dependent mitochondrion-to-nucleus retrograde signaling. Surprisingly, our in vitro protein kinase assays uncovered that Mn2+ activates TORC1 substantially better than Mg2+, which is primarily due to its ability to lower the Km for ATP, thereby allowing more efficient ATP coordination in the catalytic cleft of TORC1. These findings, therefore, provide both a mechanism to explain our genetic observations in yeast and a rationale for how fluctuations in trace amounts of Mn can become physiologically relevant. Supporting this notion, TORC1 is also wired to feedback control mechanisms that impinge on Smf1 and Smf2. Finally, we also show that Mn2+-mediated control of TORC1 is evolutionarily conserved in mammals, which may prove relevant for our understanding of the role of Mn in human diseases.

Editor's evaluation

Your manuscript uses budding yeast to uncover a new input for the central metabolic regulator TOR complex 1 (TORC1) – manganese (Mn) levels and also demonstHelene rates that this dependence on Mn is conserved in humans. The combination of both in vivo and in vitro approaches as well as the demonstration of conservation of this phenomenon make the manuscript both broad and deep. TORC1 is already clearly a central coordinator of multiple inputs to guide cellular decisions of catabolism vs anabolism. Information on an additional way to modulate its activity is highly influential on both basic cell biology as well as therapeutic research.

https://doi.org/10.7554/eLife.80497.sa0

Introduction

Manganese (Mn) is a vital trace element that is required for the normal activity of the brain and nervous system by acting, among other mechanisms, as an essential, divalent metal cofactor for enzymes such as the mitochondrial enzyme superoxide dismutase 2 (Weisiger and Fridovich, 1973), the apical activator of the DNA damage response serine/threonine kinase ATM (Chan et al., 2000) or the Mn2+-activated glutamine synthetase (Wedler and Denman, 1984). However, Mn2+ becomes toxic when enriched in the human body (Couper, 1837). While mitochondria have been proposed as a preferential organelle where Mn2+ accumulates and unfolds its toxicity by increasing oxidative stress and thus mitochondrial dysfunction (Aguirre and Culotta, 2012), the molecular mechanisms of Mn2+ toxicity in humans are also related to protein misfolding, endoplasmic reticulum (ER) stress, and apoptosis (Harischandra et al., 2019). Mn2+ homeostasis is coordinated by a complex interplay between various metal transporters for Mn2+ uptake and intracellular Mn2+ distribution and represents an essential task of eukaryotic cells, which is also of vital importance specifically for neuronal cell health (Horning et al., 2015).

Much of our knowledge on Mn2+ transport across the plasma membrane into the ER, the Golgi, endosomes, and vacuoles comes from studies in Saccharomyces cerevisiae (outlined in Figure 1A). Typically, Mn2+ is shuttled across membranes by transporters that belong to the natural resistance-associated macrophage protein (NRAMP) family, which are highly conserved metal transporters responsible for iron (Fe) and Mn2+ uptake (Supek et al., 1996). Not surprisingly, therefore, NRAMP orthologs have been found to cross-complement functions in yeast, mice, and humans (Sacher et al., 2000). One of the best-studied NRAMPs is the yeast plasma membrane protein Smf1. Interestingly, extracellular Fe or Mn2+ supplementation triggers Bsd2 adaptor protein-dependent, Rsp5-mediated ubiquitination of Smf1, which initiates its sorting through the endocytic multivesicular body pathway and subsequent lysosomal degradation (Eguez et al., 2004; Liu and Culotta, 1999). The Smf1 paralogs Smf2 and Smf3 are less well studied, but Smf2 is predominantly localized at endosomes and its levels decrease under conditions of Mn or Fe overload (Liu et al., 1997; Moreno-Cermeño et al., 2010). Within cells, the P-type ATPase Pmr1 (also known as Bsd1) represents a key transporter that shuttles Ca2+ and Mn2+ ions into the Golgi lumen. Its loss leads to increased levels of Mn2+ in the cytoplasm due to defective detoxification (Lapinskas et al., 1995). Noteworthy, several phenotypes associated with loss of Pmr1 have been shown to arise as a consequence of Mn2+ accumulation in the cytoplasm, including telomere shortening, genome instability, and bypass of the superoxide dismutase Sod1 requirement (Bolton et al., 2002; García-Rodríguez et al., 2012; Lapinskas et al., 1995; Lue et al., 2005).

Figure 1 with 3 supplements see all
Download asset Open asset
Natural resistance-associated macrophage protein (NRAMP) transporters link Mn2+-import to rapamycin resistance.

(A) Schematical outline of yeast Mn2+ transporters and their intracellular localization. PM, plasma membrane; PVE, pre-vacuolar endosomes; ER, endoplasmic reticulum. Note that Bsd2 is a specific adaptor protein for Rsp5-mediated Smf1 and Smf2 ubiquitination in response to Mn2+ overload. The Golgi Mn2+ transporter Gdt1 is omitted for clarity. (B–D) Growth on MnCl2 and/or rapamycin-containing medium (RAP). Ten-fold dilutions of exponentially growing cells are shown. Strains and compound concentrations are indicated. Note that the medium used in (D) was supplemented with 10 mM CaCl2. Data obtained in a medium without CaCl2 are shown in Figure 1—figure supplement 3. (E) Southern blot analysis of telomere length. Genomic DNA was derived from cells grown in a medium supplemented or not with CaCl2 and cleaved by XhoI before agarose gel electrophoresis. The 1.3 kb average length of telomeres from WT cells (dashed white line, black arrow) and size marker (M) are shown. (F) Growth of pmr1∆ smf2∆ double mutants transformed with plasmids expressing yeast Smf2, Mus musculus SLC11A1, or SLC11A2 on rapamycin-containing medium. Complementary data showing that pmr1∆ rapamycin resistance is not linked to Gap1 or Tor1 localization is provided in Figure 1—figure supplement 1. Rapamycin sensitivity of bsd2∆ cells overexpressing the Vcx1-M1 transporter are shown in Figure 1—figure supplement 2.

Figure 1—source data 1

Uncropped autoradiography image shown in Figure 1E.

https://cdn.elifesciences.org/articles/80497/elife-80497-fig1-data1-v1.pdf
Figure 1—source data 2

Raw autoradiography image shown in Figure 1E.

https://cdn.elifesciences.org/articles/80497/elife-80497-fig1-data2-v1.zip

TORC1/mTORC1 is a central, highly conserved controller of cell growth and aging in eukaryotes. It coordinates the cellular response to multiple inputs, including nutritional availability, bioenergetic status, oxygen levels, and, in multicellular organisms, the presence of growth factors (Albert and Hall, 2015; Laplante and Sabatini, 2012). In response to these diverse cues, TORC1 regulates cell growth and proliferation, metabolism, protein synthesis, autophagy, and DNA damage responses (Liu and Sabatini, 2020; Sancak et al., 2008). In S. cerevisiae, which played a pivotal role in the discovery and dissection of the TOR signaling network (Heitman et al., 1991), TORC1 is mainly localized on the surfaces of vacuoles and endosomes (Betz and Hall, 2013; Hatakeyama et al., 2019) where it integrates, among other cues, amino acid signals through the Rag GTPases and Pib2 (Nicastro et al., 2017; Tanigawa et al., 2021). In mammals, amino acids also activate the Rag GTPases, which then recruit mTORC1 to the lysosomal surface where it can be allosterically activated by the small GTPase Rheb (Ras homolog expressed in brain) that mediates the presence of growth factors and sufficient energy levels (Binda et al., 2009; Sancak et al., 2008; Sancak et al., 2010; Wedaman et al., 2003). Interestingly, mTORC1 regulates cellular Fe homeostasis (Bayeva et al., 2012), but how it may be able to sense Fe levels remains largely unknown. In addition, although TORC1/mTORC1 requires divalent metal ions to coordinate ATP at its catalytic cleft (Brunn et al., 1996; Withers et al., 1997), it is currently not known whether these or any other trace elements may play a physiological or regulatory role in controlling its activity.

In yeast, genetic evidence links high levels of cytoplasmic Mn2+ to TORC1 function, as loss of Pmr1 confers rapamycin resistance (Devasahayam et al., 2007). However, the underlying molecular mechanism(s) by which Mn2+ may mediate rapamycin resistance remains to be explored. Here, we show that Mn2+ uptake by NRAMP transporters modulates rapamycin resistance and that, in turn, TORC1 inhibition by rapamycin regulates NRAMP transporter availability. Moreover, intracellular Mn2+ excess antagonizes rapamycin-induced autophagy, mitophagy, and Rtg1-3 transcription factor complex-dependent retrograde response activation. Surprisingly, our in vitro analyses reveal that TORC1 protein kinase activity is strongly activated in the presence of MnCl2. In our attempts to understand the mechanisms underlying these observations, we discovered that Mn2+, when compared to Mg2+, significantly boosts the affinity of TORC1 for ATP. Combined, our findings also indicate that TORC1 activity is regulated by and regulates intracellular Mn2+ levels, defining Mn2+ homeostasis as a key factor in cell growth control. Importantly, our studies in human cells indicate that Mn2+-driven TORC1 activation is likely conserved throughout evolution, opening new perspectives for our understanding of Mn2+ toxicities and their role in neurodegenerative disorders and aging.

Results

NRAMP transporters regulate cytoplasmic Mn2+ levels and rapamycin resistance

Yeast cells lacking the Golgi-localized P-type ATPase Pmr1, which transports Ca2+ and Mn2+ ions from the cytoplasm to the Golgi lumen, are resistant to the TORC1 inhibitor rapamycin (Devasahayam et al., 2006; Devasahayam et al., 2007), a phenotype that is generally associated with increased TORC1 activity. In pmr1∆ mutants, defective Mn2+ shuttling at the Golgi leads to protein sorting defects and accumulation of the general amino acid permease Gap1 at the plasma membrane (Kaufman et al., 1994). In theory, this may translate into unrestrained uptake and intracellular accumulation of amino acids, and thus hyperactivation of TORC1. However, arguing against such a model, we found cells lacking both Pmr1 and Gap1 to remain resistant to low doses of rapamycin (Figure 1—figure supplement 1A). We then asked whether loss of Pmr1 may affect the expression levels or cellular localization of TORC1. Our results indicated that GFP-Tor1 protein levels and localization to vacuolar and endosomal membranes remained unaltered in exponentially growing and rapamycin-treated WT and pmr1∆ cells (Figure 1—figure supplement 1B and C). Given the roughly fivefold increased intracellular Mn2+ levels in cells lacking Pmr1 (Lapinskas et al., 1995), we then considered the possibility that Mn2+ may have a more direct role in TORC1 activation. We, therefore, assessed the rapamycin sensitivity of cells lacking the adaptor protein Bsd2, which mediates Rsp5-dependent degradation in response to high Mn2+ levels of both the plasma membrane- and endosomal membrane-resident NRAMP Mn2+ transporters Smf1 and Smf2, respectively (Figure 1A; Liu et al., 1997). Interestingly, bsd2∆ cells were as sensitive to rapamycin as WT cells, but, unlike WT cells, could be rendered rapamycin resistant by the addition of 1 mM MnCl2 in the growth medium (Figure 1B and Figure 1—figure supplement 2). This effect was strongly reduced in the absence of Smf2 (Figure 1C), suggesting that Smf2-dependent endosomal Mn2+ export and, consequently, cytoplasmic accumulation of Mn2+ may be required for rapamycin resistance under these conditions. In line with such a model, we found that overexpression of the vacuolar membrane-resident Vcx1-M1 transporter, which imports Mn2+ into the vacuolar lumen, suppressed the Mn2+-induced rapamycin resistance of bsd2∆ mutants and increased their sensitivity to rapamycin in the absence of extracellular MnCl2 supply (Figure 1—figure supplement 2).

As schematically outlined in Figure 1A, several metal transporters have been associated with Mn2+ transport in yeast, including those localized at the plasma membrane (Smf1 and Pho84), the endosomes (Smf2 and Atx2), the Golgi (Pmr1 and Gdt1), the vacuole (Ccc1 and Vcx1), the ER (Spf1), and possibly the mitochondria (Mtm1). To identify which of these transporters contributes to the rapamycin resistance of pmr1∆ cells, we next monitored the growth of double mutants lacking Pmr1 and any of the corresponding metal transporters in the presence of rapamycin (Figure 1D). Interestingly, only loss of Smf1 or Smf2 reestablished rapamycin sensitivity in pmr1∆ cells, while loss of Gdt1 or Ccc1 even slightly enhanced the rapamycin resistance phenotype of pmr1∆ cells. Of note, growth was monitored on CaCl2-supplemented media that improved the growth of pmr1∆ cells lacking Smf1 or Smf2 without affecting their sensitivity to rapamycin, which also rules out the possibility that Ca2+ is associated with the observed rapamycin resistance phenotype (Figure 1D and Figure 1—figure supplement 3). Taken together, our data indicate that increased intracellular Mn2+ levels in pmr1∆ cells lead to rapamycin resistance and that this phenotype can be suppressed either by reducing Mn2+ import through loss of Smf1 or, possibly, by increasing Mn2+ sequestration in endosomes through loss of Smf2 as previously suggested (Luk and Culotta, 2001). To confirm our prediction that loss of Smf2 reduces cytoplasmic Mn2+ levels, we measured MnCl2-dependent telomere length shortening as an indirect proxy for cytoplasmic and nuclear Mn levels (García-Rodríguez et al., 2015). Accordingly, telomere length was significantly decreased in pmr1∆ cells (when compared to WT cells), increased in smf2∆ cells, and similar between pmr1∆ smf2∆ and WT cells (Figure 1E). These data, therefore, corroborate our assumption that loss of Smf2 suppresses the high cytoplasmic and nuclear Mn2+ levels of pmr1∆ cells.

The function of metal transporters is highly conserved across evolution as exemplified by the fact that the expression of the human Pmr1 ortholog, the secretory pathway Ca2+/Mn2+ ATPase ATP2C1/SPCA1 (ATPase secretory pathway Ca2+ transporting 1), can substitute for Pmr1 function in yeast (Muncanovic et al., 2019). A similar degree of functional conservation from lower to higher eukaryotes exists for NRAMP transporters (Sacher et al., 2000). Because Smf2 is of specific interest in the context of the present study, we asked whether the orthologous mouse proteins, that is, the divalent metal transporter SLC11A1 (NRAMP1) and SLC11A2 (DMT1) isoforms (solute carrier family 11 member 1 and 2, respectively), can restore rapamycin resistance in pmr1∆ smf2∆ double mutants. Expression of SLC11A1 did not rescue the lack of Smf2, leading to poor growth even in the absence of rapamycin. However, the SLC11A2 isoform complemented Smf2 function in these assays (Figure 1F), indicating that Pmr1 and Smf2 are evolutionarily conserved transporters that are required for Mn2+ homeostasis.

Elevated levels of intracellular Mn2+ antagonize rapamycin-induced autophagy, mitophagy, and Rtg1-3 retrograde signaling

Growth inhibition by rapamycin mimics starvation conditions and leads to the degradation and recycling of a wide spectrum of biological macromolecules via autophagy. In this context, the pmr1∆ mutant has previously been found to be defective in nutrient depletion-induced mitophagy (Kanki et al., 2010). We thus wondered if rapamycin-induced autophagic processing may also be defective in pmr1∆ mutants. We took advantage of a GFP-Atg8 fusion construct (Cheong and Klionsky, 2008) to monitor autophagy through GFP-Atg8 synthesis and processing in cells that had been subjected to rapamycin treatment for up to 6 hr. Rapamycin-induced GFP-Atg8 expression was strongly reduced in pmr1∆ cells and this phenotype was mitigated in the pmr1∆ smf2∆ double mutant (Figure 2A and B), suggesting that the initiation of autophagy is compromised by elevated cytoplasmic Mn2+ levels. Next, we assessed mitophagy by following the expression and degradation of the GFP-tagged mitochondrial membrane protein Om45 (Kanki et al., 2009). Rapamycin treatment led to a time-dependent up-regulation of Om45-GFP protein levels in all tested strains (Figure 2C and D). However, the accumulation of the cleaved GFP protein was strongly reduced in the pmr1∆ single mutant, while this effect was again suppressed in the pmr1∆ smf2∆ double mutant. Combined, our results therefore suggest that the intracellular Mn2+ flux modulates both rapamycin-induced autophagy and mitophagy.

Figure 2
Download asset Open asset
Intracellular manganese (Mn) excess antagonizes rapamycin-induced autophagy, mitophagy, and Rtg1-3 retrograde signaling.

(A) Exponentially growing WT and indicated mutant strains expressing plasmid-encoded GFP-Atg8 were treated for up to 6 hr with 200 ng/ml rapamycin (RAP). GFP-Atg8 and cleaved GFP (*GFP) protein levels were analyzed by immunoblotting. Glucose-6-phosphate dehydrogenase (G-6-PDH) levels were used as a loading control. (B) Quantification of GFP-Atg8 and *GFP levels after a 6 hr rapamycin treatment. Total GFP signal (Atg8-GFP + *GFP) normalized to WT levels (left) and percentage of *GFP relative to the total GFP signal (right) are plotted. Data represent means ± SEM of independent experiments (n=4). Statistical analysis: two-tailed t-test (paired for normalized data, unpaired for GFP* percentage). *p<0.05; **p<0.01; ***p<0.001. (C) Exponentially growing WT and indicated mutant strains expressing Om45-GFP from the endogenous locus were treated and processed as in (A). (D) Quantification of Om45-GFP and *GFP levels after a 6 hr rapamycin treatment. Details as in (B) with n=3. (E) Representative fluorescence microscope images of WT, pmr1∆, smf2∆, and pmr1∆ smf2∆ mutants expressing an episomic Rtg3-GFP reporter construct. Exponentially growing cells were treated or not (control) for 30 min with 200 ng/ml rapamycin (RAP). Scale bar represents 5 µm. (F) Rtg3-GFP expressing cells were treated for up to 30 min with 200 ng/ml rapamycin. Protein levels were analyzed by immunoblotting. G-6-PDH levels were used as a loading control. (G) Quantification of Rtg3-GFP signals. Values normalized to WT levels after 15 min of rapamycin treatment (highest signal) are plotted. Data represent means ± SEM of independent experiments (n=4). Statistical analysis: paired two-tailed t-test.

Figure 2—source data 1

Quantification of blots for graphs shown in Figure 2B–D–G.

https://cdn.elifesciences.org/articles/80497/elife-80497-fig2-data1-v1.xlsx
Figure 2—source data 2

Uncropped blots shown in Figure 2A–C–F and quantified in Figure 2B–D.

https://cdn.elifesciences.org/articles/80497/elife-80497-fig2-data2-v1.pdf
Figure 2—source data 3

Raw blots shown in Figure 2A–C–F and quantified in Figure 2B–D.

https://cdn.elifesciences.org/articles/80497/elife-80497-fig2-data3-v1.zip

To identify additional responses to elevated cytosolic Mn2+ levels, we took advantage of our previously published transcriptome analysis of pmr1∆ cells (García-Rodríguez et al., 2015). Careful analysis of these datasets revealed that the expression levels of genes activated by the heterodimeric Rtg1-Rtg3 transcription factor are reduced in pmr1∆ cells (see Supplementary file 1). Since TORC1 inhibits cytoplasmic-to-nuclear translocation of Rtg1-Rtg3 (Ruiz-Roig et al., 2012), we monitored the localization and protein levels of Rtg3-GFP in exponentially growing and rapamycin-treated WT and pmr1∆ cells. Rapamycin treatment not only induced nuclear enrichment of Rtg3-GFP as reported (Figure 2E; Ruiz-Roig et al., 2012) but also significantly increased the levels of Rtg3-GFP (Figure 2F and G). Loss of Pmr1, in contrast, significantly reduced the Rtg3-GFP levels in exponentially growing and rapamycin-treated cells, which also translated into barely visible levels of Rtg3-GFP in the nucleus (Figure 2E–G). Importantly, and in line with our finding that loss of Smf2 suppresses the high cytoplasmic and nuclear Mn2+ levels of pmr1∆ cells (see above), these latter defects in pmr1∆ cells were partially suppressed by loss of Smf2. Thus, our findings posit a model in which elevated cytoplasmic Mn2+ levels antagonize autophagy, mitophagy, and Rtg1-3-dependent retrograde signaling presumably through activation of TORC1.

MnCl2 stimulates TORC1 kinase activity in vitro

The yeast Tor1 kinase is a member of the phosphatidylinositol 3-kinase (PI3K)-related kinase (PIKK) family that can phosphorylate the human eukaryotic translation initiation factor 4E binding protein (eIF4-BP/PHAS-I) in vitro (Alarcon et al., 1999). Curiously, it does so much more efficiently when the respective in vitro kinase assays contain Mn2+ rather than Mg2+ as the sole divalent cation, a property that it appears to share with PI3-kinases (Carpenter et al., 1993; Dhand et al., 1994; Foukas et al., 2004). A similar preference for Mn2+ over Mg2+ has also been observed in mTOR kinase autophosphorylation assays (Brunn et al., 1996; Withers et al., 1997). Based on these and our observations, we decided to assess whether Mn2+ may act as a metal cofactor for TORC1 activity in vitro using TORC1 purified from yeast and a truncated form of Lst4 (Lst4Loop; Nicastro et al., 2021) as a substrate. In control experiments without divalent ions, TORC1 activity remained undetectable (Figure 3A and B). The addition of MnCl2, however, not only stimulated TORC1 in vitro in a concentration-dependent manner, but also activated TORC1 dramatically more efficiently than MgCl2 (with 25-fold lower levels of MnCl2 [38 µM] than MgCl2 [980 µM] promoting half-maximal activation of TORC1; Figure 3A and B). We next considered the possibility that Mn2+ is superior to Mg2+ in favoring the coordination of ATP in the catalytic cleft or TORC1. Supporting this idea, we found that Mn2+ significantly reduced the Km for ATP (5.3-fold) of TORC1 (Figure 3C and D). Moreover, even in the presence of saturating Mg2+ levels (i.e. 4 mM), the addition of 160 µM Mn2+ was able to enhance the VMAX almost twofold and decrease the Km for ATP of TORC1 from 50.7 to 34.4 µM, which indicates that Mn2+ can efficiently compete with Mg2+ and thereby activate TORC1. Notably, the conditions used in our in vitro kinase assays are quite comparable to the in vivo situation: accordingly, intracellular Mg2+ levels in yeast are approximately around 2 mM (van Eunen et al., 2010), while the Mn2+ levels range from 26 µM in WT cells to 170 µM in pmr1∆ cells (McNaughton et al., 2010). Our in vitro assays, therefore, provide a simple rationale for why pmr1∆ cells are resistant to rapamycin: elevated Mn2+ levels in pmr1∆ favorably boost the kinetic parameters of TORC1.

Figure 3
Download asset Open asset
MnCl2 stimulates TORC1 kinase activity in vitro and in vivo.

(A) In vitro TORC1 kinase assays using [γ-32P]-ATP, recombinant Lst4Loop as substrate, and increasing concentrations (twofold dilutions) of MgCl2 or MnCl2. Substrate phosphorylation was detected by autoradiography (lower blot) and SYPRO Ruby staining is shown as loading control (upper blot). (B) Quantification of the assay shown in (A). Curve fitting and parameter calculations were performed with GraphPad Prism. Data shown are means (± SEM, n=3). (C) In vitro kinase assays (as in A) using the indicated concentrations of MgCl2 and/or MnCl2 and increasing concentrations of ATP. Substrate phosphorylation was detected by autoradiography (lower blot) and SYPRO Ruby staining is shown as loading control (upper blot). (D) Quantification of the assay shown in (C). Data shown are means (± SEM, n=3). Curve fitting and parameter calculations were performed with GraphPad Prism. KmATP are shown for each curve. VMAX [MnCl2]=1.13 ± 0.06, VMAX [MgCl2 MnCl2]=0.89 ± 0.03, VMAX [MgCl2]=0.47 ± 0.02.

Figure 3—source data 1

Quantification of autoradiographies for graphs shown in Figure 3B–D.

https://cdn.elifesciences.org/articles/80497/elife-80497-fig3-data1-v1.xlsx
Figure 3—source data 2

Uncropped gels and autoradiographies shown in Figure 3A–C and quantified in Figure 3B–D.

https://cdn.elifesciences.org/articles/80497/elife-80497-fig3-data2-v1.pdf
Figure 3—source data 3

Raw gels and autoradiographies shown in Figure 3A–C and quantified in Figure 3B–D.

https://cdn.elifesciences.org/articles/80497/elife-80497-fig3-data3-v1.zip

TORC1 regulates NRAMP transporter protein levels

To maintain appropriate intracellular Mn2+ concentrations, cells adjust Smf1 and Smf2 protein levels through Bsd2-dependent and -independent, post-translational modifications that ultimately trigger their vacuolar degradation through the endocytic multivesicular body pathway (Liu and Culotta, 1994; Liu et al., 1997). Because NRAMP transporters are important for Mn-dependent TORC1 activation, and because TORC1 is often embedded in regulatory feedback loops to ensure cellular homeostasis (Eltschinger and Loewith, 2016), we next asked whether rapamycin-mediated TORC1 inactivation may affect the levels and/or localization of Smf1 and Smf2 using a strain that expresses N-terminally tagged Smf1 (GFP-Smf1) under its own promoter from a non-endogenous locus or a strain that expresses C-terminally tagged Smf2 (Smf2-GFP) from its endogenous locus (García-Rodríguez et al., 2015; Renz et al., 2020). Rapamycin treatment triggered a strong increase in GFP-Smf1 levels (Figure 4A and B), which is likely due to transcriptional activation of Smf1 under these conditions as published earlier (Reinke et al., 2006). In line with this interpretation, we found the respective increase to be abolished when rapamycin-treated cells were co-treated with the protein synthesis inhibitor cycloheximide (CHX). In addition, because GFP-Smf1 appeared to be degraded at a similar rate in CHX-treated cells that were treated, or not, with rapamycin, our data further indicate that TORC1 does not control Smf1 levels through post-translational control of Smf1 turnover. Interestingly, GFP-Smf1 remained predominantly at the plasma membrane in rapamycin-treated cells, even though these cells also accumulated more cleaved GFP in the vacuoles (Figure 4C). We infer from these data that TORC1 inhibition activates Smf1 expression, likely as part of a feedback control loop through which TORC1 couples its activity to Mn2+ uptake. Rapamycin-treated cells that were either co-treated or not with CHX exhibited Smf2-GFP levels that steadily decreased at a similar rate, with cleaved GFP accumulating in parallel (Figure 4D and E). Since this rate appeared to be higher than the one observed in cells treated with CHX alone, our data suggest that TORC1 antagonizes the turnover of Smf2. This was further corroborated by our fluorescence microscopy analyses revealing that the GFP signal in Smf2-GFP-expressing cells shifted from late Golgi/endosomal foci (see García-Rodríguez et al., 2015) to a predominant signal within the vacuolar lumen when cells were treated with rapamycin (Figure 4F). Whether this event is an indirect consequence of higher Mn2+ uptake under these conditions (see above), or potentially part of a local feedback control mechanism of endosomal TORC1 (Hatakeyama et al., 2019), remains to be addressed in future studies.

Figure 4
Download asset Open asset
TORC1 regulates natural resistance-associated macrophage protein (NRAMP) transporter levels.

(A) GFP-Smf1 expressing cells were cultivated for 5–6 hr in a synthetic medium devoid of manganese sulfate before being treated with 200 ng/ml rapamycin (RAP), 25 µg/ml cycloheximide (CHX), or both compounds (RAP + CHX) for the indicated times. GFP-Smf1 and cleaved GFP (*GFP) protein levels were analyzed by immunoblotting using an anti-GFP antibody. Alcohol dehydrogenase (Adh1) protein levels, probed with anti-Adh1 antibodies, served as a loading control. (B) Quantification of GFP-Smf1. Percentages of GFP-Smf1 relative to the total GFP signal (GFP-Smf1 + GFP) are plotted. Data represent means ± SEM of independent experiments (n=3). Statistical analysis: unpaired two-tailed t-test. *p<0.05; **p<0.01, ***p<0.001, ****p<0.0001. (C) Microscopic analysis of GFP-Smf1 localization. Cells co-expressing GFP-Smf1 and the vacuolar marker Vph1-mCherry were grown exponentially in a manganese-free medium for 5–6 hr, then treated with 200 ng/ml rapamycin for 2 hr. Scale bar represents 5 µm. (D–E) Cells expressing Smf2-GFP from its endogenous locus were grown, treated, and processed as in (A). (F) Microscopic analysis of Smf2-GFP localization. Cells co-expressing Smf2-GFP and the vacuolar marker Vph1-mCherry were cultivated, treated, and examined as in (C).

Figure 4—source data 1

Quantification of blots for graphs shown in Figure 4B–E.

https://cdn.elifesciences.org/articles/80497/elife-80497-fig4-data1-v1.xlsx
Figure 4—source data 2

Uncropped blots shown in Figure 4A–D and quantified in Figure 4B–E.

https://cdn.elifesciences.org/articles/80497/elife-80497-fig4-data2-v1.pdf
Figure 4—source data 3

Raw blots shown in Figure 4A–D and quantified in Figure 4B–E.

https://cdn.elifesciences.org/articles/80497/elife-80497-fig4-data3-v1.zip

Mn2+ activates mTORC1 signaling in human cells

To assess whether the response of TORC1 to Mn2+ is conserved among eukaryotes, we investigated if externally supplied MnCl2 activates mTORC1 signaling in mammalian cells. For this purpose, we used the human cell lines U2OS and HEK293T, which are widely used for the cellular dissection of mTORC1-mediated mechanisms in response to nutritional inputs (Bodineau et al., 2021). First, we examined the sufficiency of Mn2+ to maintain the activity of the mTORC1 pathway by incubating U2OS cells in an amino acid starvation medium supplemented with increasing amounts of MnCl2 (0–1 mM) for 2 hr. mTORC1 activity was assessed by monitoring phosphorylation of the mTORC1 downstream targets RPS6KB (ribosomal protein S6 kinase B; phospho-Threonine389) and RPS6 (ribosomal protein S6; phospho-Serine235–236). As shown in Figure 5A, and as expected, both RPS6KB and RPS6 were fully phosphorylated at those specific residues in cells incubated in the presence of amino acids and completely de-phosphorylated in cells incubated in the absence of amino acids, without MnCl2. In agreement with a positive action of Mn2+ toward mTORC1 in human cells, we observed a robust and dose-dependent increase in both RPS6KB and RPS6 phosphorylation in amino acid-starved cells incubated in the presence of MnCl2 at concentrations higher than 0.05 mM, with maximum phosphorylation observed at 0.5 mM of MnCl2. Confirming this result, we observed a similar response of RPS6KB and RPS6 phosphorylation to MnCl2 treatment in HEK293T cells, except that the maximum response was reached at 1 mM (Figure 5B). These results indicate that Mn2+ is sufficient to maintain the activity of the mTORC1 pathway in the absence of amino acid inputs, at least during short periods (2 hr). To corroborate this conclusion, we also tested the phosphorylation of additional downstream targets of mTORC1 in response to a fixed concentration of MnCl2 (0.35 mM) in U2OS cells. Amino acid starvation of U2OS cells with MnCl2 was sufficient to maintain the phosphorylation of the downstream targets of mTORC1 RPS6KB, RPS6, EIF4EBP1, and ULK1 (unc-51 like autophagy activating kinase 1) (Figure 5C). In line with our finding that MnCl2 retained AKT1 (AKT serine/threonine kinase 1) phosphorylation in amino acid-starved cells, Mn2+ has been reported to activate the mTORC1 upstream kinase AKT1, which is also a known mTORC2 downstream target (Bryan et al., 2018; Gaubitz et al., 2016). However, AKT1 phosphorylation appeared to be much less pronounced than the phosphorylation of the mTORC1 downstream targets, validating the specificity of Mn toward mTORC1. Whether Mn2+ may stimulate TORC2 activity remains to be explored.

Figure 5
Download asset Open asset
MnCl2 maintains mTORC1 activity during starvation in human cells.

(A–B) Human U2OS (A) and HEK293T (B) cells were starved for all amino acids and supplemented with increasing concentrations of MnCl2 as indicated for 2 hr. Phosphorylation of the mTORC1 downstream targets RPS6KB (ribosomal protein S6 kinase B) and RPS6 (ribosomal protein S6) was assessed by immunoblot analysis. A control with cells incubated in the presence of all proteinogenic amino acids (+AA) was included as a positive control. (C) Human U2OS were starved for all amino acids (-AA) and supplemented with 0.35 mM of MnCl2 for 2 hr. Phosphorylation of RPS6KB, RPS6, EIF4EBP1, ULK1, and AKT1 was assessed by immunoblot analysis. A control with cells incubated in the presence of all proteinogenic amino acids (+AA) was included as a positive control. (D–E) Human U2OS cells were treated as in (C) for 4 hr either in the absence (D) or the presence (E) of chloroquine (CQ). Autophagic marker MAP1LC3I/II was then analyzed by immunoblot. (F–G) GFP-MAP1LC3 expressing U2OS cells were incubated as in (D). GFP-MAP1LC3 aggregation was assessed by confocal microscopy (F) and quantified using ImageJ software (G). Scale bar indicates 10 µm. Values were normalized to -AA condition. Graphs represent mean ± SD, with n=3 (*p<0.05, ANOVA followed by Tukey’s test). (H) Model of Mn2+-driven TORC1 activation. The Smf1/2 natural resistance-associated macrophage protein (NRAMP) transporter-dependent increase in cytoplasmatic Mn2+ levels favors TORC1-Mn2+ binding and ATP coordination, leading to TORC1 hyperactivation. NRAMP transporters are part of a feedback control mechanism impinged by TPRC1 (dashed lines).

Figure 5—source data 1

Quantification of microscopy images for graph shown in Figure 5G.

https://cdn.elifesciences.org/articles/80497/elife-80497-fig5-data1-v1.xlsx
Figure 5—source data 2

Uncropped blots shown in Figure 5A–E.

https://cdn.elifesciences.org/articles/80497/elife-80497-fig5-data2-v1.pdf
Figure 5—source data 3

Raw blots shown in Figure 5A–E.

https://cdn.elifesciences.org/articles/80497/elife-80497-fig5-data3-v1.zip

Finally, to assess the physiological relevance of mTORC1 activation in response to Mn2+, we analyzed the effect of MnCl2 treatment in autophagy, a cellular process inhibited by TORC1 both in yeast and in mammalian cells (Noda and Ohsumi, 1998; Villar et al., 2017). To this end, we analyzed the autophagic marker MAP1LC3I/II (microtubule-associated protein 1 light chain 3) (Klionsky et al., 2016). During autophagy initiation, MAP1LC3I is lipidated, thereby increasing the levels of MAP1LC3II. As previously reported, the withdrawal of amino acids led to a rapid increase in MAP1LC3II levels, indicating an increase in autophagy initiation (Figure 5D). Of note, the addition of MnCl2 completely abolished the increase in MAP1LC3II levels, thus confirming that Mn2+ prevented the initiation of autophagy downstream of mTORC1. These results were also observed in cells incubated in the presence of chloroquine, an inhibitor of the fusion of autophagosomes with the lysosome, thus confirming that Mn2+ influences autophagy initiation, the process controlled by mTORC1 (Figure 5E). In addition, we analyzed the aggregation of MAP1LC3 upon autophagosome formation in U2OS cells stably expressing a GFP-MAP1LC3 construct. GFP aggregation indicates autophagosome formation in these cells. Similar to what we observed with endogenous MAP1LC3, GFP aggregation was increased during amino acid withdrawal and this increase was completely abolished by MnCl2 treatment (Figure 5F–G). This result further confirms that the Mn-dependent activation of mTORC1 in human cells is physiologically relevant for autophagy inhibition. Altogether, our results show that Mn2+ is sufficient to keep mTORC1 activated in the absence of other inputs in human cells and to inhibit autophagy downstream of mTORC1. These findings indicate that Mn2+-mediated activation of TORC1 is evolutionarily conserved from yeast to humans.

Discussion

Studies with yeast lacking the divalent Ca/Mn ion Golgi transporter Pmr1, which displays an increase in intracellular Mn2+ levels due to impaired Mn2+ detoxification (McNaughton et al., 2010), have pinpointed a functional link between Mn2+ homeostasis and TORC1 signaling (Devasahayam et al., 2006; Devasahayam et al., 2007). However, the underlying mechanism(s) of how Mn2+ impinges on TORC1 has so far remained elusive. Our study identifies Mn2+ as a divalent metal cofactor that stimulates the enzymatic activity of the TORC1 complex in vitro and suggests that Mn2+ functions similarly in vivo both in yeast and in mammalian cells. Our results support a model in which the PI3K-related protein kinase Tor1 is activated by Mg2+, but requires Mn2+ as a metal cofactor for maximal activity as this allows it to better coordinate ATP (Figure 5H). While it seemingly shares this feature with PI3Ks (Carpenter et al., 1993; Dhand et al., 1994; Foukas et al., 2004), serine/threonine protein kinases are generally known to be preferably activated by Mg2+ rather than Mn2+ (Knape et al., 2017). We deem it therefore possible that the respective Mn2+-driven activation of TORC1 is more specifically related to the architecture of its catalytic center. Resolution of this issue will therefore require future molecular dynamic modeling and/or structural analyses.

Our current study also highlights a need for coordinated control of TORC1 activity and cytoplasmic Mn2+ levels. The latter critically depend on a set of conserved NRAMP transporters, such as yeast Pmr1 and Smf1/2, and their mammalian homologs ATP2C1/SPCA1 (Muncanovic et al., 2019) and SLC11A2 (DMT1; Nevo and Nelson, 2006; and this work). In yeast, cytoplasmic Mn levels can be increased by the loss of Pmr1, which causes a defect in sequestration of Mn2+ in the Golgi. Alternatively, they can also be boosted by increased Smf1-mediated Mn2+ uptake combined with Smf2-mediated Mn2+ depletion in endosomes following the loss of Bsd2, an adaptor protein for the NEDD4 family E3 ubiquitin ligase Rsp5 (Liu et al., 1997) that normally favors vacuolar degradation of Smf1/2 (Jensen et al., 2009; Portnoy et al., 2000). In both cases, that is, loss of Pmr1 or of Bsd2 (specifically upon addition of Mn2+ in the medium), enhanced cytoplasmic Mn2+ levels mediate higher TORC1 activity and hence the resistance of cells to low doses of rapamycin. Conversely, our expression and localization studies of GFP-Smf1 and Smf2-GFP indicate that TORC1, while being controlled by Mn2+ levels, also employs feedback control mechanisms that regulate Smf1 expression and Smf2 turnover. These observations are consistent with the recent paradigm shift assigning TORC1 an essential role in cellular and organismal homeostasis (Eltschinger and Loewith, 2016) and extend this role of TORC1 to Mn metabolism. A more detailed understanding of these regulatory circuits involving TORC1 and NRAMP transporters (and vice versa) will, however, require future analyses of the specific subcellular pools of Mn2+ within different organelles using electron-nuclear double resonance spectroscopy (McNaughton et al., 2010) or inductively coupled plasma mass spectrometry (Liu et al., 2019). Of note, Mn2+ also acts as a cofactor for glutamine synthetase (Wedler and Denman, 1984) that produces the TORC1-stimulating amino acid glutamine (Jewell et al., 2015). Hence, Mn2+ homeostasis, amino acid metabolism, and TORC1 may be subjected to even more intricate, multilayered feedback regulatory circuits.

Our finding that Mn2+ activates TORC1/mTORC1 may have important implications in different biological contexts. For instance, previous work has shown that chronic exposure to high levels of Mn2+ causes autophagic dysfunction and hence accumulation of compromised mitochondria in mammalian astrocytes due to reduced nuclear localization of TFEB (transcription factor EB), a key transcription factor that coordinates the expression of genes involved in autophagy (Zhang et al., 2020). Because mTORC1 inhibits TFEB (Settembre et al., 2012) and mitochondrial quality can be improved by rapamycin-induced TFEB induction (and consequent stimulation of autophagy) (Siddiqui et al., 2015), our study now provides a simple rationale for the observed accumulation of damaged mitochondria upon Mn2+ exposure. Accordingly, excess Mn2+ antagonizes autophagy and mitophagy at least in part through mTORC1 activation and subsequent TFEB inhibition, which prevents proper disposal of hazardous and reactive oxygen species-producing mitochondria. This model also matches well with our previous observation that rapamycin restricts cell death associated with anomalous mTORC1 hyperactivation (Villar et al., 2017). Finally, our data indicate that Mn2+-driven TORC1 activation and the ensuing inhibition of auto- and mitophagy are also employed by yeast cells, which highlights the primordial nature of these processes.

Another area where our findings may be relevant relates to the use of Mn2+ to stimulate antitumor immune responses. Recent studies have shown that Mn2+ is indispensable for the host defense against cytosolic, viral double-stranded DNA as it mediates activation of the DNA sensor CGAS (cyclic GMP-AMP synthase) and its downstream adaptor protein STING1 (stimulator of interferon response cGAMP interactor 1) (Wang et al., 2018). Since Mn2+ stimulates the innate immune sensing of tumors, Mn administration has been suggested to provide an antitumoral effect and improve the treatment of cancer patients (Lv et al., 2020). Nevertheless, mTORC1 hyperactivation is known to promote tumor progression (Mossmann et al., 2018), and carcinoma and melanoma formation have previously been associated with mutations in the human PMR1 ortholog ATP2C1 that cause Hailey-Hailey disease (Mohr et al., 2011). Based on our findings, it is therefore possible that tumor formation in these patients may be causally linked to Mn2+-dependent DNA replication defects (García-Rodríguez et al., 2012), stress response (Cialfi et al., 2016), and mTORC1 activation.

In addition to the potential relevance of our findings in the context of chronic Mn2+ exposure and immune stimulation, our findings may also provide new perspectives to our understanding of specific neuropathies. For instance, exposure to Mn dust or Mn containing smoke, as a byproduct of metal welding, is well known to cause a parkinsonian-like syndrome named manganism, a toxic condition of Mn poisoning with dyskinesia (Racette et al., 2001). Interestingly, while dyskinesia has been connected to L-dopamine-mediated activation of mTORC1 (Santini et al., 2009), our findings suggest that Mn2+-driven mTORC1 hyperactivation may impair autophagy and thereby contribute to neurological diseases (Cheng et al., 2020). In line with this reasoning, compounds that inhibit mTORC1 activity, and thus stimulate autophagy, have been suggested as therapeutics for the treatment of Parkinson-like neurological symptoms (Ravikumar et al., 2004). In this context, Huntington disease (HD) is another example of patients suffering from a proteinopathy characterized by parkinsonian-like neurological syndromes (McColgan and Tabrizi, 2018). In HD patients, expansion of the polyglutamine tract in the N-terminus of the huntingtin protein leads to protein aggregation (Macdonald, 1993) and, intriguingly, HD patients exhibit reduced Mn2+ levels in the brain (Bowman et al., 2011). This raises the question of whether the respective cells aim to evade Mn-driven mTORC1 activation, for example, by reducing Mn uptake or sequestration of Mn2+ within organelles, to stimulate huntingtin protein degradation via autophagy. Finally, Mn2+ also contributes to prion formation in yeast (Chakrabortee et al., 2016), and elevated Mn2+ levels have been detected in the blood and the central nervous system of Creutzfeldt-Jakob patients (Hesketh et al., 2008). It will therefore be exciting to study the cell type-specific impact of Mn2+-driven mTORC1 activation on metabolism, genome stability, checkpoint signaling, and the immune response, all processes that play a key role in neurological diseases and aging-related processes.

Materials and methods

Antibodies

Primary antibodies against GFP (Takara Bio, 632380, AB_10013427; 1:5000), G-6-PDH (Sigma-Aldrich, A9521, AB_258454; 1:5000), Adh1 (Millipore, 126745, AB_564196; 1:200000), RPS6 (Cell Signaling Technology, 2217, AB_331355; 1:1000), phospho-RPS6 (Ser235-236) (Cell Signaling Technology, 4856, AB_2181037; 1:1000), RPS6KB (Cell Signaling Technology, 2708, AB_390722; 1:1000), phospho-RPS6KB (Thr389) (Cell Signaling Technology, 9205, AB_330944; 1:1000), EIF4EBP1 (Cell Signaling Technology, 9452, AB_331692; 1:1000), phospho-EIF4EBP1 (Thr37/46) (Cell Signaling Technology, 2855, AB_560835; 1:1000), phospho-EIF4EBP1 (Ser65) (Cell Signaling Technology, 9451, AB_330947; 1:1000), AKT1 (Cell Signaling Technology, 4691, AB_915783; 1:1000), phospho-AKT(Ser473) (Cell Signaling Technology, 4060, AB_2315049; 1:1000), phospho-AKT(Thr308) (Cell Signaling Technology, 13038, AB_2629447; 1:1000), ULK1 (Cell Signaling Technology, 8359, AB_11178668; 1:1000), phospho-ULK1(Ser757) (Cell Signaling Technology, 6888, AB_10829226; 1:1000), MAP1LC3 AB (Cell Signaling Technology, 12741, AB_2617131; 1:1000), β-actin (Cell Signaling Technology, 4967, AB_330288; 1:1000) were used.

Yeast strains, plasmids, and growth conditions

Request a detailed protocol

Yeast strains and plasmids used in this study are available upon request and listed in Supplementary file 2; Supplementary file 3, respectively. Gene disruption and tagging were performed with standard high-efficiency recombination methods. To generate strain MP6988, pSIVu-SMF1p-GFP-SMF1 was digested with PacI and transformed into smf1∆ strain YOL182C. Yeast cells were grown to mid-log phase in synthetic defined medium (SD; 0.17% yeast nitrogen base, 0.5% ammonium sulfate, 2% glucose, 0.2% drop-out mix) at 30°C. To induce autophagy, mitophagy, and Rtg1-Rtg3 retrograde signaling, cells were treated with 200 ng/ml rapamycin (Biosynth Carbosynth, AE27685) for the indicated time. For telomere length analyses, cells were grown for 3 days in rich medium (YPAD; 1% yeast extract, 2% peptone, 2% glucose, 0.004% adenine sulfate) with or without the addition of 10 mM CaCl2. For imaging of Rtg3-GFP, cells were grown at 26°C in SD-MSG-ura medium (0.17% yeast nitrogen base, 0.5% monosodium glutamate, 2% glucose, 0.2% drop-out mix-ura) to exponential phase and treated or not with 200 ng/ml rapamycin for 30 min. For GFP1-Smf1 and Smf2-GFP analyses, cells were grown in SD-ura medium. Overnight precultures were quickly spun and diluted into SD-ura medium devoid of manganese sulfate (0.19% yeast nitrogen base without manganese sulfate [Formedium; CYN2001], 0.5% ammonium sulfate, 2% glucose, and 0.2% drop-out mix-ura). After 5–6 hr of growth, cells were treated with either rapamycin (200 ng/ml), CHX (25 µg/ml), or both compounds for the indicated times.

Yeast cell lysate preparation and immunoblotting

Request a detailed protocol

Cells grown to mid-log phase were treated with 6.7% trichloroacetic acid (TCA, final concentration), pelleted, washed with 99% acetone, dried, dissolved in urea buffer (6 M urea, 50 mM Tris-HCl pH 7.5, 1% SDS, 1 mM PMSF, and 10 mM NaF) and disrupted with glass beads using a Yasui Kikai homogenizer. Cell lysates were heated at 65°C for 10 min in Laemmli SDS sample buffer, centrifuged at 15,000 g for 1 min, and the supernatants were subjected to SDS-PAGE and immunoblotted. Heat denaturation of samples was omitted to detect GFP-Smf1 and Smf2-GFP. Chemiluminescence signals were captured in an Amersham ImageQuant 800 Imager and quantified with ImageQuant TL software (Cytiva).

Drug sensitivity assays

Request a detailed protocol

Yeast cells grown to mid-log phase were adjusted to an initial A600 of 0.2, serially diluted 1:10, and spotted onto plates without or with rapamycin at the indicated concentrations (see figure legends). One mM MnCl2 and/or 10 mM CaCl2 were added to the medium when indicated. Plates were then incubated at 30°C for 3–4 days. Two or more biological replicates were performed for all conditions.

Analysis of telomere length

Request a detailed protocol

Genomic DNA was isolated from yeast strains grown in YPAD for 3 days with or without the addition of 10 mM CaCl2. DNA was digested with XhoI, separated on a 1% agarose-Tris borate EDTA gel, transferred to a Hybond XL (Amersham Biosciences) membrane, and hybridized with a 32P-labeled DNA probe specific for the terminal Y’ telomere fragment. The probe was generated by random hexanucleotide-primed DNA synthesis using a short Y’-specific DNA template, which was generated by PCR from genomic yeast DNA using the primers Y up (5’-TGCCGTGCAACAAACACTAAATCAA-3’) and Y’ low (5’-CGCTCGAGAAAGTTGGAGTTTTTCA-3’). Two biological replicates of the whole experiment were conducted.

In vitro TORC1 kinase assays

Request a detailed protocol

TORC1 was purified and kinase assays were performed as previously described (Nicastro et al., 2021) with minor modifications. For the kinase assays in the presence of various concentrations of magnesium or manganese, reactions were performed in a total volume of 20 µl with kinase buffer (50 mM HEPES/NaOH [pH 7.5], 150 mM NaCl), 400 ng of purified His6-Lst4Loop, 60 ng TORC1 (quantified based on the Tor1 subunit) and 640, 320, 160, 80, 40, or 20 µM MgCl2/MnCl2. The reactions were started by adding 1.4 µl of ATP mix (18 mM ATP, 3.3 mCi [γ-32P]-ATP [Hartmann Analytic, SRP-501]). For the kinase assays in the presence of various concentrations of ATP, reactions containing 4 mM MgCl2, 160 µM MnCl2, or both were started by adding 1.4 µl of stock ATP mix (5.7 mM ATP, 3.3 mCi [γ-32P]-ATP [Hartmann Analytic, SRP-501]) or twofold serial dilutions. After the addition of sample buffer, proteins were separated by SDS-PAGE, stained with SYPRO Ruby (Sigma-Aldrich, S492) (loading control), and analyzed using a phosphoimager (Typhoon FLA 9500; GE Healthcare). Band intensities from three technical replicates were quantified with ImageJ and data were analyzed with GraphPad Prism using the Michaelis-Menten non-linear fitting.

Cell culture

Request a detailed protocol

U2OS and HEK293T cell lines were obtained from the American Type Culture Collection (ATCC). GFP-MAP1LC3-expressing U2OS cells were kindly provided by Dr Eyal Gottlieb (Cancer Research UK, Glasgow, UK). All the cell lines were grown in high glucose DMEM base medium (Sigma-Aldrich, D6546) supplemented with 10% of fetal bovine serum, glutamine (2 mM), penicillin (Sigma-Aldrich, 100 µg/ml), and streptomycin (100 µg/ml), at 37°C, 5% CO2 in a humidified atmosphere. Amino acid starvation was performed with EBSS medium (Sigma-Aldrich, E2888) supplemented with glucose at a final concentration of 4.5 g/l. When indicated, the starvation medium was complemented with MnCl2 to a final concentration of 0.05–1 mM, chloroquine (Sigma-Aldrich; 10 µM), and amino acids, by adding MEM Amino Acids (Sigma-Aldrich, M5550), plus MEM Non-essential Amino Acid Solution (Sigma-Aldrich, M7145) and glutamine (2 mM). The identities of the cell lines bought from ATCC were authenticated by STR profiling. The identity of the GFP-MAP1LC3-expressing U2OS cells was verified by the donating research group. In addition, all cell lines were tested negative for mycoplasma contamination.

Confocal and fluorescence microscopy

Request a detailed protocol

Yeast cells: For imaging of GFP-Tor1, GFP-Smf1, and Smf2-GFP, images were captured with an inverted spinning disk confocal microscope (Nikon Ti-E, VisiScope CSU-W1, Puchheim, Germany) that was equipped with an Evolve 512 EM-CDD camera (Photometrics), and a 100 × 1.3 NA oil immersion Nikon CFI series objective (Egg, Switzerland). Images were then processed using the FIJI-ImageJ software. For imaging of Rtg3-GFP, images were obtained by projection of a focal plane image derived from wide-field fluorescence microscopy (DM-6000B, Leica) at 100× magnification using L5 filters and a digital charge-coupled device camera (DFC350, Leica). Pictures were processed with LAS AF (Leica).

Human cells: 8 × 105 cells were grown in coverslips for 24 hr and treated for 4 hr as indicated. Thereafter, cells were fixed with 4% paraformaldehyde (Sigma-Aldrich) in PBS for 10 min at room temperature. For GFP-MAP1LC3 assessment, after three washes with PBS, coverslips were mounted with Prolong containing DAPI (Invitrogen). Samples were imaged with a Zeiss Apotome microscope. GFP aggregation in microscopy images was assessed using ImageJ software.

Statistical analyses

Request a detailed protocol

Statistical analyses were performed using GraphPad Prism 7.0. Statistical significance was determined from at least three independent biological replicates using either Student’s t-test or ANOVA followed by Tukey’s multiple comparison test. Two-tailed Student’s t-test was used for comparison of the means of two different experimental conditions. Paired t-test was used for the pairwise comparison of normalized data. ANOVA test was used for the analyses of three variables. Differences with a p-value lower than 0.05 were considered significant. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. The number of independent experiments (n), specific statistical tests, and significance are described in the figure legends.

Data availability

All data generated or analyzed during this study are included in the manuscript and supporting files. Source data files have been provided for Figure 1, Figure 1-figure supplement 1, Figure 2, Figure 3, Figure 4 and Figure 5. The data set entitled 'Expression data of pmr1∆ mutants', originally published in García-Rodríguez et al (2012) and reused in this study is accessible at Gene Expression Omnibus under the accession code GSE29420.

The following previously published data sets were used

References

    1. Couper J
    (1837)
    On the effects of black oxide of manganese when inhaled into the lungs
    British Annals of Medicine, Pharmacy, Vital Statistics, and General Science 1:41–42.
    1. Klionsky DJ
    2. Abdelmohsen K
    3. Abe A
    4. Abedin MJ
    5. Abeliovich H
    6. Acevedo Arozena A
    7. Adachi H
    8. Adams CM
    9. Adams PD
    10. Adeli K
    11. Adhihetty PJ
    12. Adler SG
    13. Agam G
    14. Agarwal R
    15. Aghi MK
    16. Agnello M
    17. Agostinis P
    18. Aguilar PV
    19. Aguirre-Ghiso J
    20. Airoldi EM
    21. Ait-Si-Ali S
    22. Akematsu T
    23. Akporiaye ET
    24. Al-Rubeai M
    25. Albaiceta GM
    26. Albanese C
    27. Albani D
    28. Albert ML
    29. Aldudo J
    30. Algül H
    31. Alirezaei M
    32. Alloza I
    33. Almasan A
    34. Almonte-Beceril M
    35. Alnemri ES
    36. Alonso C
    37. Altan-Bonnet N
    38. Altieri DC
    39. Alvarez S
    40. Alvarez-Erviti L
    41. Alves S
    42. Amadoro G
    43. Amano A
    44. Amantini C
    45. Ambrosio S
    46. Amelio I
    47. Amer AO
    48. Amessou M
    49. Amon A
    50. An Z
    51. Anania FA
    52. Andersen SU
    53. Andley UP
    54. Andreadi CK
    55. Andrieu-Abadie N
    56. Anel A
    57. Ann DK
    58. Anoopkumar-Dukie S
    59. Antonioli M
    60. Aoki H
    61. Apostolova N
    62. Aquila S
    63. Aquilano K
    64. Araki K
    65. Arama E
    66. Aranda A
    67. Araya J
    68. Arcaro A
    69. Arias E
    70. Arimoto H
    71. Ariosa AR
    72. Armstrong JL
    73. Arnould T
    74. Arsov I
    75. Asanuma K
    76. Askanas V
    77. Asselin E
    78. Atarashi R
    79. Atherton SS
    80. Atkin JD
    81. Attardi LD
    82. Auberger P
    83. Auburger G
    84. Aurelian L
    85. Autelli R
    86. Avagliano L
    87. Avantaggiati ML
    88. Avrahami L
    89. Awale S
    90. Azad N
    91. Bachetti T
    92. Backer JM
    93. Bae D-H
    94. Bae J-S
    95. Bae O-N
    96. Bae SH
    97. Baehrecke EH
    98. Baek S-H
    99. Baghdiguian S
    100. Bagniewska-Zadworna A
    101. Bai H
    102. Bai J
    103. Bai X-Y
    104. Bailly Y
    105. Balaji KN
    106. Balduini W
    107. Ballabio A
    108. Balzan R
    109. Banerjee R
    110. Bánhegyi G
    111. Bao H
    112. Barbeau B
    113. Barrachina MD
    114. Barreiro E
    115. Bartel B
    116. Bartolomé A
    117. Bassham DC
    118. Bassi MT
    119. Bast RC
    120. Basu A
    121. Batista MT
    122. Batoko H
    123. Battino M
    124. Bauckman K
    125. Baumgarner BL
    126. Bayer KU
    127. Beale R
    128. Beaulieu J-F
    129. Beck GR
    130. Becker C
    131. Beckham JD
    132. Bédard P-A
    133. Bednarski PJ
    134. Begley TJ
    135. Behl C
    136. Behrends C
    137. Behrens GM
    138. Behrns KE
    139. Bejarano E
    140. Belaid A
    141. Belleudi F
    142. Bénard G
    143. Berchem G
    144. Bergamaschi D
    145. Bergami M
    146. Berkhout B
    147. Berliocchi L
    148. Bernard A
    149. Bernard M
    150. Bernassola F
    151. Bertolotti A
    152. Bess AS
    153. Besteiro S
    154. Bettuzzi S
    155. Bhalla S
    156. Bhattacharyya S
    157. Bhutia SK
    158. Biagosch C
    159. Bianchi MW
    160. Biard-Piechaczyk M
    161. Billes V
    162. Bincoletto C
    163. Bingol B
    164. Bird SW
    165. Bitoun M
    166. Bjedov I
    167. Blackstone C
    168. Blanc L
    169. Blanco GA
    170. Blomhoff HK
    171. Boada-Romero E
    172. Böckler S
    173. Boes M
    174. Boesze-Battaglia K
    175. Boise LH
    176. Bolino A
    177. Boman A
    178. Bonaldo P
    179. Bordi M
    180. Bosch J
    181. Botana LM
    182. Botti J
    183. Bou G
    184. Bouché M
    185. Bouchecareilh M
    186. Boucher M-J
    187. Boulton ME
    188. Bouret SG
    189. Boya P
    190. Boyer-Guittaut M
    191. Bozhkov PV
    192. Brady N
    193. Braga VM
    194. Brancolini C
    195. Braus GH
    196. Bravo-San Pedro JM
    197. Brennan LA
    198. Bresnick EH
    199. Brest P
    200. Bridges D
    201. Bringer M-A
    202. Brini M
    203. Brito GC
    204. Brodin B
    205. Brookes PS
    206. Brown EJ
    207. Brown K
    208. Broxmeyer HE
    209. Bruhat A
    210. Brum PC
    211. Brumell JH
    212. Brunetti-Pierri N
    213. Bryson-Richardson RJ
    214. Buch S
    215. Buchan AM
    216. Budak H
    217. Bulavin DV
    218. Bultman SJ
    219. Bultynck G
    220. Bumbasirevic V
    221. Burelle Y
    222. Burke RE
    223. Burmeister M
    224. Bütikofer P
    225. Caberlotto L
    226. Cadwell K
    227. Cahova M
    228. Cai D
    229. Cai J
    230. Cai Q
    231. Calatayud S
    232. Camougrand N
    233. Campanella M
    234. Campbell GR
    235. Campbell M
    236. Campello S
    237. Candau R
    238. Caniggia I
    239. Cantoni L
    240. Cao L
    241. Caplan AB
    242. Caraglia M
    243. Cardinali C
    244. Cardoso SM
    245. Carew JS
    246. Carleton LA
    247. Carlin CR
    248. Carloni S
    249. Carlsson SR
    250. Carmona-Gutierrez D
    251. Carneiro LA
    252. Carnevali O
    253. Carra S
    254. Carrier A
    255. Carroll B
    256. Casas C
    257. Casas J
    258. Cassinelli G
    259. Castets P
    260. Castro-Obregon S
    261. Cavallini G
    262. Ceccherini I
    263. Cecconi F
    264. Cederbaum AI
    265. Ceña V
    266. Cenci S
    267. Cerella C
    268. Cervia D
    269. Cetrullo S
    270. Chaachouay H
    271. Chae H-J
    272. Chagin AS
    273. Chai C-Y
    274. Chakrabarti G
    275. Chamilos G
    276. Chan EY
    277. Chan MT
    278. Chandra D
    279. Chandra P
    280. Chang C-P
    281. Chang RC-C
    282. Chang TY
    283. Chatham JC
    284. Chatterjee S
    285. Chauhan S
    286. Che Y
    287. Cheetham ME
    288. Cheluvappa R
    289. Chen C-J
    290. Chen G
    291. Chen G-C
    292. Chen G
    293. Chen H
    294. Chen JW
    295. Chen J-K
    296. Chen M
    297. Chen M
    298. Chen P
    299. Chen Q
    300. Chen Q
    301. Chen S-D
    302. Chen S
    303. Chen SS-L
    304. Chen W
    305. Chen W-J
    306. Chen WQ
    307. Chen W
    308. Chen X
    309. Chen Y-H
    310. Chen Y-G
    311. Chen Y
    312. Chen Y
    313. Chen Y
    314. Chen Y-J
    315. Chen Y-Q
    316. Chen Y
    317. Chen Z
    318. Chen Z
    319. Cheng A
    320. Cheng CH
    321. Cheng H
    322. Cheong H
    323. Cherry S
    324. Chesney J
    325. Cheung CHA
    326. Chevet E
    327. Chi HC
    328. Chi S-G
    329. Chiacchiera F
    330. Chiang H-L
    331. Chiarelli R
    332. Chiariello M
    333. Chieppa M
    334. Chin L-S
    335. Chiong M
    336. Chiu GN
    337. Cho D-H
    338. Cho S-G
    339. Cho WC
    340. Cho Y-Y
    341. Cho Y-S
    342. Choi AM
    343. Choi E-J
    344. Choi E-K
    345. Choi J
    346. Choi ME
    347. Choi S-I
    348. Chou T-F
    349. Chouaib S
    350. Choubey D
    351. Choubey V
    352. Chow K-C
    353. Chowdhury K
    354. Chu CT
    355. Chuang T-H
    356. Chun T
    357. Chung H
    358. Chung T
    359. Chung Y-L
    360. Chwae Y-J
    361. Cianfanelli V
    362. Ciarcia R
    363. Ciechomska IA
    364. Ciriolo MR
    365. Cirone M
    366. Claerhout S
    367. Clague MJ
    368. Clària J
    369. Clarke PG
    370. Clarke R
    371. Clementi E
    372. Cleyrat C
    373. Cnop M
    374. Coccia EM
    375. Cocco T
    376. Codogno P
    377. Coers J
    378. Cohen EE
    379. Colecchia D
    380. Coletto L
    381. Coll NS
    382. Colucci-Guyon E
    383. Comincini S
    384. Condello M
    385. Cook KL
    386. Coombs GH
    387. Cooper CD
    388. Cooper JM
    389. Coppens I
    390. Corasaniti MT
    391. Corazzari M
    392. Corbalan R
    393. Corcelle-Termeau E
    394. Cordero MD
    395. Corral-Ramos C
    396. Corti O
    397. Cossarizza A
    398. Costelli P
    399. Costes S
    400. Cotman SL
    401. Coto-Montes A
    402. Cottet S
    403. Couve E
    404. Covey LR
    405. Cowart LA
    406. Cox JS
    407. Coxon FP
    408. Coyne CB
    409. Cragg MS
    410. Craven RJ
    411. Crepaldi T
    412. Crespo JL
    413. Criollo A
    414. Crippa V
    415. Cruz MT
    416. Cuervo AM
    417. Cuezva JM
    418. Cui T
    419. Cutillas PR
    420. Czaja MJ
    421. Czyzyk-Krzeska MF
    422. Dagda RK
    423. Dahmen U
    424. Dai C
    425. Dai W
    426. Dai Y
    427. Dalby KN
    428. Dalla Valle L
    429. Dalmasso G
    430. D'Amelio M
    431. Damme M
    432. Darfeuille-Michaud A
    433. Dargemont C
    434. Darley-Usmar VM
    435. Dasarathy S
    436. Dasgupta B
    437. Dash S
    438. Dass CR
    439. Davey HM
    440. Davids LM
    441. Dávila D
    442. Davis RJ
    443. Dawson TM
    444. Dawson VL
    445. Daza P
    446. de Belleroche J
    447. de Figueiredo P
    448. de Figueiredo RCBQ
    449. de la Fuente J
    450. De Martino L
    451. De Matteis A
    452. De Meyer GR
    453. De Milito A
    454. De Santi M
    455. de Souza W
    456. De Tata V
    457. De Zio D
    458. Debnath J
    459. Dechant R
    460. Decuypere J-P
    461. Deegan S
    462. Dehay B
    463. Del Bello B
    464. Del Re DP
    465. Delage-Mourroux R
    466. Delbridge LM
    467. Deldicque L
    468. Delorme-Axford E
    469. Deng Y
    470. Dengjel J
    471. Denizot M
    472. Dent P
    473. Der CJ
    474. Deretic V
    475. Derrien B
    476. Deutsch E
    477. Devarenne TP
    478. Devenish RJ
    479. Di Bartolomeo S
    480. Di Daniele N
    481. Di Domenico F
    482. Di Nardo A
    483. Di Paola S
    484. Di Pietro A
    485. Di Renzo L
    486. DiAntonio A
    487. Díaz-Araya G
    488. Díaz-Laviada I
    489. Diaz-Meco MT
    490. Diaz-Nido J
    491. Dickey CA
    492. Dickson RC
    493. Diederich M
    494. Digard P
    495. Dikic I
    496. Dinesh-Kumar SP
    497. Ding C
    498. Ding W-X
    499. Ding Z
    500. Dini L
    501. Distler JH
    502. Diwan A
    503. Djavaheri-Mergny M
    504. Dmytruk K
    505. Dobson RC
    506. Doetsch V
    507. Dokladny K
    508. Dokudovskaya S
    509. Donadelli M
    510. Dong XC
    511. Dong X
    512. Dong Z
    513. Donohue TM
    514. Doran KS
    515. D'Orazi G
    516. Dorn GW
    517. Dosenko V
    518. Dridi S
    519. Drucker L
    520. Du J
    521. Du L-L
    522. Du L
    523. du Toit A
    524. Dua P
    525. Duan L
    526. Duann P
    527. Dubey VK
    528. Duchen MR
    529. Duchosal MA
    530. Duez H
    531. Dugail I
    532. Dumit VI
    533. Duncan MC
    534. Dunlop EA
    535. Dunn WA
    536. Dupont N
    537. Dupuis L
    538. Durán RV
    539. Durcan TM
    540. Duvezin-Caubet S
    541. Duvvuri U
    542. Eapen V
    543. Ebrahimi-Fakhari D
    544. Echard A
    545. Eckhart L
    546. Edelstein CL
    547. Edinger AL
    548. Eichinger L
    549. Eisenberg T
    550. Eisenberg-Lerner A
    551. Eissa NT
    552. El-Deiry WS
    553. El-Khoury V
    554. Elazar Z
    555. Eldar-Finkelman H
    556. Elliott CJ
    557. Emanuele E
    558. Emmenegger U
    559. Engedal N
    560. Engelbrecht A-M
    561. Engelender S
    562. Enserink JM
    563. Erdmann R
    564. Erenpreisa J
    565. Eri R
    566. Eriksen JL
    567. Erman A
    568. Escalante R
    569. Eskelinen E-L
    570. Espert L
    571. Esteban-Martínez L
    572. Evans TJ
    573. Fabri M
    574. Fabrias G
    575. Fabrizi C
    576. Facchiano A
    577. Færgeman NJ
    578. Faggioni A
    579. Fairlie WD
    580. Fan C
    581. Fan D
    582. Fan J
    583. Fang S
    584. Fanto M
    585. Fanzani A
    586. Farkas T
    587. Faure M
    588. Favier FB
    589. Fearnhead H
    590. Federici M
    591. Fei E
    592. Felizardo TC
    593. Feng H
    594. Feng Y
    595. Feng Y
    596. Ferguson TA
    597. Fernández AF
    598. Fernandez-Barrena MG
    599. Fernandez-Checa JC
    600. Fernández-López A
    601. Fernandez-Zapico ME
    602. Feron O
    603. Ferraro E
    604. Ferreira-Halder CV
    605. Fesus L
    606. Feuer R
    607. Fiesel FC
    608. Filippi-Chiela EC
    609. Filomeni G
    610. Fimia GM
    611. Fingert JH
    612. Finkbeiner S
    613. Finkel T
    614. Fiorito F
    615. Fisher PB
    616. Flajolet M
    617. Flamigni F
    618. Florey O
    619. Florio S
    620. Floto RA
    621. Folini M
    622. Follo C
    623. Fon EA
    624. Fornai F
    625. Fortunato F
    626. Fraldi A
    627. Franco R
    628. Francois A
    629. François A
    630. Frankel LB
    631. Fraser ID
    632. Frey N
    633. Freyssenet DG
    634. Frezza C
    635. Friedman SL
    636. Frigo DE
    637. Fu D
    638. Fuentes JM
    639. Fueyo J
    640. Fujitani Y
    641. Fujiwara Y
    642. Fujiya M
    643. Fukuda M
    644. Fulda S
    645. Fusco C
    646. Gabryel B
    647. Gaestel M
    648. Gailly P
    649. Gajewska M
    650. Galadari S
    651. Galili G
    652. Galindo I
    653. Galindo MF
    654. Galliciotti G
    655. Galluzzi L
    656. Galluzzi L
    657. Galy V
    658. Gammoh N
    659. Gandy S
    660. Ganesan AK
    661. Ganesan S
    662. Ganley IG
    663. Gannagé M
    664. Gao F-B
    665. Gao F
    666. Gao J-X
    667. García Nannig L
    668. García Véscovi E
    669. Garcia-Macía M
    670. Garcia-Ruiz C
    671. Garg AD
    672. Garg PK
    673. Gargini R
    674. Gassen NC
    675. Gatica D
    676. Gatti E
    677. Gavard J
    678. Gavathiotis E
    679. Ge L
    680. Ge P
    681. Ge S
    682. Gean P-W
    683. Gelmetti V
    684. Genazzani AA
    685. Geng J
    686. Genschik P
    687. Gerner L
    688. Gestwicki JE
    689. Gewirtz DA
    690. Ghavami S
    691. Ghigo E
    692. Ghosh D
    693. Giammarioli AM
    694. Giampieri F
    695. Giampietri C
    696. Giatromanolaki A
    697. Gibbings DJ
    698. Gibellini L
    699. Gibson SB
    700. Ginet V
    701. Giordano A
    702. Giorgini F
    703. Giovannetti E
    704. Girardin SE
    705. Gispert S
    706. Giuliano S
    707. Gladson CL
    708. Glavic A
    709. Gleave M
    710. Godefroy N
    711. Gogal RM
    712. Gokulan K
    713. Goldman GH
    714. Goletti D
    715. Goligorsky MS
    716. Gomes AV
    717. Gomes LC
    718. Gomez H
    719. Gomez-Manzano C
    720. Gómez-Sánchez R
    721. Gonçalves DA
    722. Goncu E
    723. Gong Q
    724. Gongora C
    725. Gonzalez CB
    726. Gonzalez-Alegre P
    727. Gonzalez-Cabo P
    728. González-Polo RA
    729. Goping IS
    730. Gorbea C
    731. Gorbunov NV
    732. Goring DR
    733. Gorman AM
    734. Gorski SM
    735. Goruppi S
    736. Goto-Yamada S
    737. Gotor C
    738. Gottlieb RA
    739. Gozes I
    740. Gozuacik D
    741. Graba Y
    742. Graef M
    743. Granato GE
    744. Grant GD
    745. Grant S
    746. Gravina GL
    747. Green DR
    748. Greenhough A
    749. Greenwood MT
    750. Grimaldi B
    751. Gros F
    752. Grose C
    753. Groulx J-F
    754. Gruber F
    755. Grumati P
    756. Grune T
    757. Guan J-L
    758. Guan K-L
    759. Guerra B
    760. Guillen C
    761. Gulshan K
    762. Gunst J
    763. Guo C
    764. Guo L
    765. Guo M
    766. Guo W
    767. Guo X-G
    768. Gust AA
    769. Gustafsson AB
    770. Gutierrez E
    771. Gutierrez MG
    772. Gwak H-S
    773. Haas A
    774. Haber JE
    775. Hadano S
    776. Hagedorn M
    777. Hahn DR
    778. Halayko AJ
    779. Hamacher-Brady A
    780. Hamada K
    781. Hamai A
    782. Hamann A
    783. Hamasaki M
    784. Hamer I
    785. Hamid Q
    786. Hammond EM
    787. Han F
    788. Han W
    789. Handa JT
    790. Hanover JA
    791. Hansen M
    792. Harada M
    793. Harhaji-Trajkovic L
    794. Harper JW
    795. Harrath AH
    796. Harris AL
    797. Harris J
    798. Hasler U
    799. Hasselblatt P
    800. Hasui K
    801. Hawley RG
    802. Hawley TS
    803. He C
    804. He CY
    805. He F
    806. He G
    807. He R-R
    808. He X-H
    809. He Y-W
    810. He Y-Y
    811. Heath JK
    812. Hébert M-J
    813. Heinzen RA
    814. Helgason GV
    815. Hensel M
    816. Henske EP
    817. Her C
    818. Herman PK
    819. Hernández A
    820. Hernandez C
    821. Hernández-Tiedra S
    822. Hetz C
    823. Hiesinger PR
    824. Higaki K
    825. Hilfiker S
    826. Hill BG
    827. Hill JA
    828. Hill WD
    829. Hino K
    830. Hofius D
    831. Hofman P
    832. Höglinger GU
    833. Höhfeld J
    834. Holz MK
    835. Hong Y
    836. Hood DA
    837. Hoozemans JJ
    838. Hoppe T
    839. Hsu C
    840. Hsu C-Y
    841. Hsu L-C
    842. Hu D
    843. Hu G
    844. Hu H-M
    845. Hu H
    846. Hu MC
    847. Hu Y-C
    848. Hu Z-W
    849. Hua F
    850. Hua Y
    851. Huang C
    852. Huang H-L
    853. Huang K-H
    854. Huang K-Y
    855. Huang S
    856. Huang S
    857. Huang W-P
    858. Huang Y-R
    859. Huang Y
    860. Huang Y
    861. Huber TB
    862. Huebbe P
    863. Huh W-K
    864. Hulmi JJ
    865. Hur GM
    866. Hurley JH
    867. Husak Z
    868. Hussain SN
    869. Hussain S
    870. Hwang JJ
    871. Hwang S
    872. Hwang TI
    873. Ichihara A
    874. Imai Y
    875. Imbriano C
    876. Inomata M
    877. Into T
    878. Iovane V
    879. Iovanna JL
    880. Iozzo RV
    881. Ip NY
    882. Irazoqui JE
    883. Iribarren P
    884. Isaka Y
    885. Isakovic AJ
    886. Ischiropoulos H
    887. Isenberg JS
    888. Ishaq M
    889. Ishida H
    890. Ishii I
    891. Ishmael JE
    892. Isidoro C
    893. Isobe K-I
    894. Isono E
    895. Issazadeh-Navikas S
    896. Itahana K
    897. Itakura E
    898. Ivanov AI
    899. Iyer AKV
    900. Izquierdo JM
    901. Izumi Y
    902. Izzo V
    903. Jäättelä M
    904. Jaber N
    905. Jackson DJ
    906. Jackson WT
    907. Jacob TG
    908. Jacques TS
    909. Jagannath C
    910. Jain A
    911. Jana NR
    912. Jang BK
    913. Jani A
    914. Janji B
    915. Jannig PR
    916. Jansson PJ
    917. Jean S
    918. Jendrach M
    919. Jeon J-H
    920. Jessen N
    921. Jeung E-B
    922. Jia K
    923. Jia L
    924. Jiang H
    925. Jiang H
    926. Jiang L
    927. Jiang T
    928. Jiang X
    929. Jiang X
    930. Jiang X
    931. Jiang Y
    932. Jiang Y
    933. Jiménez A
    934. Jin C
    935. Jin H
    936. Jin L
    937. Jin M
    938. Jin S
    939. Jinwal UK
    940. Jo E-K
    941. Johansen T
    942. Johnson DE
    943. Johnson GV
    944. Johnson JD
    945. Jonasch E
    946. Jones C
    947. Joosten LA
    948. Jordan J
    949. Joseph A-M
    950. Joseph B
    951. Joubert AM
    952. Ju D
    953. Ju J
    954. Juan H-F
    955. Juenemann K
    956. Juhász G
    957. Jung HS
    958. Jung JU
    959. Jung Y-K
    960. Jungbluth H
    961. Justice MJ
    962. Jutten B
    963. Kaakoush NO
    964. Kaarniranta K
    965. Kaasik A
    966. Kabuta T
    967. Kaeffer B
    968. Kågedal K
    969. Kahana A
    970. Kajimura S
    971. Kakhlon O
    972. Kalia M
    973. Kalvakolanu DV
    974. Kamada Y
    975. Kambas K
    976. Kaminskyy VO
    977. Kampinga HH
    978. Kandouz M
    979. Kang C
    980. Kang R
    981. Kang T-C
    982. Kanki T
    983. Kanneganti T-D
    984. Kanno H
    985. Kanthasamy AG
    986. Kantorow M
    987. Kaparakis-Liaskos M
    988. Kapuy O
    989. Karantza V
    990. Karim MR
    991. Karmakar P
    992. Kaser A
    993. Kaushik S
    994. Kawula T
    995. Kaynar AM
    996. Ke P-Y
    997. Ke Z-J
    998. Kehrl JH
    999. Keller KE
    1000. Kemper JK
    1001. Kenworthy AK
    1002. Kepp O
    1003. Kern A
    1004. Kesari S
    1005. Kessel D
    1006. Ketteler R
    1007. Kettelhut IdoC
    1008. Khambu B
    1009. Khan MM
    1010. Khandelwal VK
    1011. Khare S
    1012. Kiang JG
    1013. Kiger AA
    1014. Kihara A
    1015. Kim AL
    1016. Kim CH
    1017. Kim DR
    1018. Kim D-H
    1019. Kim EK
    1020. Kim HY
    1021. Kim H-R
    1022. Kim J-S
    1023. Kim JH
    1024. Kim JC
    1025. Kim JH
    1026. Kim KW
    1027. Kim MD
    1028. Kim M-M
    1029. Kim PK
    1030. Kim SW
    1031. Kim S-Y
    1032. Kim Y-S
    1033. Kim Y
    1034. Kimchi A
    1035. Kimmelman AC
    1036. Kimura T
    1037. King JS
    1038. Kirkegaard K
    1039. Kirkin V
    1040. Kirshenbaum LA
    1041. Kishi S
    1042. Kitajima Y
    1043. Kitamoto K
    1044. Kitaoka Y
    1045. Kitazato K
    1046. Kley RA
    1047. Klimecki WT
    1048. Klinkenberg M
    1049. Klucken J
    1050. Knævelsrud H
    1051. Knecht E
    1052. Knuppertz L
    1053. Ko J-L
    1054. Kobayashi S
    1055. Koch JC
    1056. Koechlin-Ramonatxo C
    1057. Koenig U
    1058. Koh YH
    1059. Köhler K
    1060. Kohlwein SD
    1061. Koike M
    1062. Komatsu M
    1063. Kominami E
    1064. Kong D
    1065. Kong HJ
    1066. Konstantakou EG
    1067. Kopp BT
    1068. Korcsmaros T
    1069. Korhonen L
    1070. Korolchuk VI
    1071. Koshkina NV
    1072. Kou Y
    1073. Koukourakis MI
    1074. Koumenis C
    1075. Kovács AL
    1076. Kovács T
    1077. Kovacs WJ
    1078. Koya D
    1079. Kraft C
    1080. Krainc D
    1081. Kramer H
    1082. Kravic-Stevovic T
    1083. Krek W
    1084. Kretz-Remy C
    1085. Krick R
    1086. Krishnamurthy M
    1087. Kriston-Vizi J
    1088. Kroemer G
    1089. Kruer MC
    1090. Kruger R
    1091. Ktistakis NT
    1092. Kuchitsu K
    1093. Kuhn C
    1094. Kumar AP
    1095. Kumar A
    1096. Kumar A
    1097. Kumar D
    1098. Kumar D
    1099. Kumar R
    1100. Kumar S
    1101. Kundu M
    1102. Kung H-J
    1103. Kuno A
    1104. Kuo S-H
    1105. Kuret J
    1106. Kurz T
    1107. Kwok T
    1108. Kwon TK
    1109. Kwon YT
    1110. Kyrmizi I
    1111. La Spada AR
    1112. Lafont F
    1113. Lahm T
    1114. Lakkaraju A
    1115. Lam T
    1116. Lamark T
    1117. Lancel S
    1118. Landowski TH
    1119. Lane DJR
    1120. Lane JD
    1121. Lanzi C
    1122. Lapaquette P
    1123. Lapierre LR
    1124. Laporte J
    1125. Laukkarinen J
    1126. Laurie GW
    1127. Lavandero S
    1128. Lavie L
    1129. LaVoie MJ
    1130. Law BYK
    1131. Law HK-W
    1132. Law KB
    1133. Layfield R
    1134. Lazo PA
    1135. Le Cam L
    1136. Le Roch KG
    1137. Le Stunff H
    1138. Leardkamolkarn V
    1139. Lecuit M
    1140. Lee B-H
    1141. Lee C-H
    1142. Lee EF
    1143. Lee GM
    1144. Lee H-J
    1145. Lee H
    1146. Lee JK
    1147. Lee J
    1148. Lee J-H
    1149. Lee JH
    1150. Lee M
    1151. Lee M-S
    1152. Lee PJ
    1153. Lee SW
    1154. Lee S-J
    1155. Lee S-J
    1156. Lee SY
    1157. Lee SH
    1158. Lee SS
    1159. Lee S-J
    1160. Lee S
    1161. Lee Y-R
    1162. Lee YJ
    1163. Lee YH
    1164. Leeuwenburgh C
    1165. Lefort S
    1166. Legouis R
    1167. Lei J
    1168. Lei Q-Y
    1169. Leib DA
    1170. Leibowitz G
    1171. Lekli I
    1172. Lemaire SD
    1173. Lemasters JJ
    1174. Lemberg MK
    1175. Lemoine A
    1176. Leng S
    1177. Lenz G
    1178. Lenzi P
    1179. Lerman LO
    1180. Lettieri Barbato D
    1181. Leu JI-J
    1182. Leung HY
    1183. Levine B
    1184. Lewis PA
    1185. Lezoualc'h F
    1186. Li C
    1187. Li F
    1188. Li F-J
    1189. Li J
    1190. Li K
    1191. Li L
    1192. Li M
    1193. Li M
    1194. Li Q
    1195. Li R
    1196. Li S
    1197. Li W
    1198. Li W
    1199. Li X
    1200. Li Y
    1201. Lian J
    1202. Liang C
    1203. Liang Q
    1204. Liao Y
    1205. Liberal J
    1206. Liberski PP
    1207. Lie P
    1208. Lieberman AP
    1209. Lim HJ
    1210. Lim K-L
    1211. Lim K
    1212. Lima RT
    1213. Lin C-S
    1214. Lin C-F
    1215. Lin F
    1216. Lin F
    1217. Lin F-C
    1218. Lin K
    1219. Lin K-H
    1220. Lin P-H
    1221. Lin T
    1222. Lin W-W
    1223. Lin Y-S
    1224. Lin Y
    1225. Linden R
    1226. Lindholm D
    1227. Lindqvist LM
    1228. Lingor P
    1229. Linkermann A
    1230. Liotta LA
    1231. Lipinski MM
    1232. Lira VA
    1233. Lisanti MP
    1234. Liton PB
    1235. Liu B
    1236. Liu C
    1237. Liu C-F
    1238. Liu F
    1239. Liu H-J
    1240. Liu J
    1241. Liu J-J
    1242. Liu J-L
    1243. Liu K
    1244. Liu L
    1245. Liu L
    1246. Liu Q
    1247. Liu R-Y
    1248. Liu S
    1249. Liu S
    1250. Liu W
    1251. Liu X-D
    1252. Liu X
    1253. Liu X-H
    1254. Liu X
    1255. Liu X
    1256. Liu X
    1257. Liu Y
    1258. Liu Y
    1259. Liu Z
    1260. Liu Z
    1261. Liuzzi JP
    1262. Lizard G
    1263. Ljujic M
    1264. Lodhi IJ
    1265. Logue SE
    1266. Lokeshwar BL
    1267. Long YC
    1268. Lonial S
    1269. Loos B
    1270. López-Otín C
    1271. López-Vicario C
    1272. Lorente M
    1273. Lorenzi PL
    1274. Lõrincz P
    1275. Los M
    1276. Lotze MT
    1277. Lovat PE
    1278. Lu B
    1279. Lu B
    1280. Lu J
    1281. Lu Q
    1282. Lu S-M
    1283. Lu S
    1284. Lu Y
    1285. Luciano F
    1286. Luckhart S
    1287. Lucocq JM
    1288. Ludovico P
    1289. Lugea A
    1290. Lukacs NW
    1291. Lum JJ
    1292. Lund AH
    1293. Luo H
    1294. Luo J
    1295. Luo S
    1296. Luparello C
    1297. Lyons T
    1298. Ma J
    1299. Ma Y
    1300. Ma Y
    1301. Ma Z
    1302. Machado J
    1303. Machado-Santelli GM
    1304. Macian F
    1305. MacIntosh GC
    1306. MacKeigan JP
    1307. Macleod KF
    1308. MacMicking JD
    1309. MacMillan-Crow LA
    1310. Madeo F
    1311. Madesh M
    1312. Madrigal-Matute J
    1313. Maeda A
    1314. Maeda T
    1315. Maegawa G
    1316. Maellaro E
    1317. Maes H
    1318. Magariños M
    1319. Maiese K
    1320. Maiti TK
    1321. Maiuri L
    1322. Maiuri MC
    1323. Maki CG
    1324. Malli R
    1325. Malorni W
    1326. Maloyan A
    1327. Mami-Chouaib F
    1328. Man N
    1329. Mancias JD
    1330. Mandelkow E-M
    1331. Mandell MA
    1332. Manfredi AA
    1333. Manié SN
    1334. Manzoni C
    1335. Mao K
    1336. Mao Z
    1337. Mao Z-W
    1338. Marambaud P
    1339. Marconi AM
    1340. Marelja Z
    1341. Marfe G
    1342. Margeta M
    1343. Margittai E
    1344. Mari M
    1345. Mariani FV
    1346. Marin C
    1347. Marinelli S
    1348. Mariño G
    1349. Markovic I
    1350. Marquez R
    1351. Martelli AM
    1352. Martens S
    1353. Martin KR
    1354. Martin SJ
    1355. Martin S
    1356. Martin-Acebes MA
    1357. Martín-Sanz P
    1358. Martinand-Mari C
    1359. Martinet W
    1360. Martinez J
    1361. Martinez-Lopez N
    1362. Martinez-Outschoorn U
    1363. Martínez-Velázquez M
    1364. Martinez-Vicente M
    1365. Martins WK
    1366. Mashima H
    1367. Mastrianni JA
    1368. Matarese G
    1369. Matarrese P
    1370. Mateo R
    1371. Matoba S
    1372. Matsumoto N
    1373. Matsushita T
    1374. Matsuura A
    1375. Matsuzawa T
    1376. Mattson MP
    1377. Matus S
    1378. Maugeri N
    1379. Mauvezin C
    1380. Mayer A
    1381. Maysinger D
    1382. Mazzolini GD
    1383. McBrayer MK
    1384. McCall K
    1385. McCormick C
    1386. McInerney GM
    1387. McIver SC
    1388. McKenna S
    1389. McMahon JJ
    1390. McNeish IA
    1391. Mechta-Grigoriou F
    1392. Medema JP
    1393. Medina DL
    1394. Megyeri K
    1395. Mehrpour M
    1396. Mehta JL
    1397. Mei Y
    1398. Meier U-C
    1399. Meijer AJ
    1400. Meléndez A
    1401. Melino G
    1402. Melino S
    1403. de Melo EJT
    1404. Mena MA
    1405. Meneghini MD
    1406. Menendez JA
    1407. Menezes R
    1408. Meng L
    1409. Meng L-H
    1410. Meng S
    1411. Menghini R
    1412. Menko AS
    1413. Menna-Barreto RF
    1414. Menon MB
    1415. Meraz-Ríos MA
    1416. Merla G
    1417. Merlini L
    1418. Merlot AM
    1419. Meryk A
    1420. Meschini S
    1421. Meyer JN
    1422. Mi M-T
    1423. Miao C-Y
    1424. Micale L
    1425. Michaeli S
    1426. Michiels C
    1427. Migliaccio AR
    1428. Mihailidou AS
    1429. Mijaljica D
    1430. Mikoshiba K
    1431. Milan E
    1432. Miller-Fleming L
    1433. Mills GB
    1434. Mills IG
    1435. Minakaki G
    1436. Minassian BA
    1437. Ming X-F
    1438. Minibayeva F
    1439. Minina EA
    1440. Mintern JD
    1441. Minucci S
    1442. Miranda-Vizuete A
    1443. Mitchell CH
    1444. Miyamoto S
    1445. Miyazawa K
    1446. Mizushima N
    1447. Mnich K
    1448. Mograbi B
    1449. Mohseni S
    1450. Moita LF
    1451. Molinari M
    1452. Molinari M
    1453. Møller AB
    1454. Mollereau B
    1455. Mollinedo F
    1456. Mongillo M
    1457. Monick MM
    1458. Montagnaro S
    1459. Montell C
    1460. Moore DJ
    1461. Moore MN
    1462. Mora-Rodriguez R
    1463. Moreira PI
    1464. Morel E
    1465. Morelli MB
    1466. Moreno S
    1467. Morgan MJ
    1468. Moris A
    1469. Moriyasu Y
    1470. Morrison JL
    1471. Morrison LA
    1472. Morselli E
    1473. Moscat J
    1474. Moseley PL
    1475. Mostowy S
    1476. Motori E
    1477. Mottet D
    1478. Mottram JC
    1479. Moussa CE-H
    1480. Mpakou VE
    1481. Mukhtar H
    1482. Mulcahy Levy JM
    1483. Muller S
    1484. Muñoz-Moreno R
    1485. Muñoz-Pinedo C
    1486. Münz C
    1487. Murphy ME
    1488. Murray JT
    1489. Murthy A
    1490. Mysorekar IU
    1491. Nabi IR
    1492. Nabissi M
    1493. Nader GA
    1494. Nagahara Y
    1495. Nagai Y
    1496. Nagata K
    1497. Nagelkerke A
    1498. Nagy P
    1499. Naidu SR
    1500. Nair S
    1501. Nakano H
    1502. Nakatogawa H
    1503. Nanjundan M
    1504. Napolitano G
    1505. Naqvi NI
    1506. Nardacci R
    1507. Narendra DP
    1508. Narita M
    1509. Nascimbeni AC
    1510. Natarajan R
    1511. Navegantes LC
    1512. Nawrocki ST
    1513. Nazarko TY
    1514. Nazarko VY
    1515. Neill T
    1516. Neri LM
    1517. Netea MG
    1518. Netea-Maier RT
    1519. Neves BM
    1520. Ney PA
    1521. Nezis IP
    1522. Nguyen HT
    1523. Nguyen HP
    1524. Nicot A-S
    1525. Nilsen H
    1526. Nilsson P
    1527. Nishimura M
    1528. Nishino I
    1529. Niso-Santano M
    1530. Niu H
    1531. Nixon RA
    1532. Njar VC
    1533. Noda T
    1534. Noegel AA
    1535. Nolte EM
    1536. Norberg E
    1537. Norga KK
    1538. Noureini SK
    1539. Notomi S
    1540. Notterpek L
    1541. Nowikovsky K
    1542. Nukina N
    1543. Nürnberger T
    1544. O'Donnell VB
    1545. O'Donovan T
    1546. O'Dwyer PJ
    1547. Oehme I
    1548. Oeste CL
    1549. Ogawa M
    1550. Ogretmen B
    1551. Ogura Y
    1552. Oh YJ
    1553. Ohmuraya M
    1554. Ohshima T
    1555. Ojha R
    1556. Okamoto K
    1557. Okazaki T
    1558. Oliver FJ
    1559. Ollinger K
    1560. Olsson S
    1561. Orban DP
    1562. Ordonez P
    1563. Orhon I
    1564. Orosz L
    1565. O'Rourke EJ
    1566. Orozco H
    1567. Ortega AL
    1568. Ortona E
    1569. Osellame LD
    1570. Oshima J
    1571. Oshima S
    1572. Osiewacz HD
    1573. Otomo T
    1574. Otsu K
    1575. Ou J-HJ
    1576. Outeiro TF
    1577. Ouyang D-Y
    1578. Ouyang H
    1579. Overholtzer M
    1580. Ozbun MA
    1581. Ozdinler PH
    1582. Ozpolat B
    1583. Pacelli C
    1584. Paganetti P
    1585. Page G
    1586. Pages G
    1587. Pagnini U
    1588. Pajak B
    1589. Pak SC
    1590. Pakos-Zebrucka K
    1591. Pakpour N
    1592. Palková Z
    1593. Palladino F
    1594. Pallauf K
    1595. Pallet N
    1596. Palmieri M
    1597. Paludan SR
    1598. Palumbo C
    1599. Palumbo S
    1600. Pampliega O
    1601. Pan H
    1602. Pan W
    1603. Panaretakis T
    1604. Pandey A
    1605. Pantazopoulou A
    1606. Papackova Z
    1607. Papademetrio DL
    1608. Papassideri I
    1609. Papini A
    1610. Parajuli N
    1611. Pardo J
    1612. Parekh VV
    1613. Parenti G
    1614. Park J-I
    1615. Park J
    1616. Park OK
    1617. Parker R
    1618. Parlato R
    1619. Parys JB
    1620. Parzych KR
    1621. Pasquet J-M
    1622. Pasquier B
    1623. Pasumarthi KB
    1624. Patschan D
    1625. Patterson C
    1626. Pattingre S
    1627. Pattison S
    1628. Pause A
    1629. Pavenstädt H
    1630. Pavone F
    1631. Pedrozo Z
    1632. Peña FJ
    1633. Peñalva MA
    1634. Pende M
    1635. Peng J
    1636. Penna F
    1637. Penninger JM
    1638. Pensalfini A
    1639. Pepe S
    1640. Pereira GJ
    1641. Pereira PC
    1642. Pérez-de la Cruz V
    1643. Pérez-Pérez ME
    1644. Pérez-Rodríguez D
    1645. Pérez-Sala D
    1646. Perier C
    1647. Perl A
    1648. Perlmutter DH
    1649. Perrotta I
    1650. Pervaiz S
    1651. Pesonen M
    1652. Pessin JE
    1653. Peters GJ
    1654. Petersen M
    1655. Petrache I
    1656. Petrof BJ
    1657. Petrovski G
    1658. Phang JM
    1659. Piacentini M
    1660. Pierdominici M
    1661. Pierre P
    1662. Pierrefite-Carle V
    1663. Pietrocola F
    1664. Pimentel-Muiños FX
    1665. Pinar M
    1666. Pineda B
    1667. Pinkas-Kramarski R
    1668. Pinti M
    1669. Pinton P
    1670. Piperdi B
    1671. Piret JM
    1672. Platanias LC
    1673. Platta HW
    1674. Plowey ED
    1675. Pöggeler S
    1676. Poirot M
    1677. Polčic P
    1678. Poletti A
    1679. Poon AH
    1680. Popelka H
    1681. Popova B
    1682. Poprawa I
    1683. Poulose SM
    1684. Poulton J
    1685. Powers SK
    1686. Powers T
    1687. Pozuelo-Rubio M
    1688. Prak K
    1689. Prange R
    1690. Prescott M
    1691. Priault M
    1692. Prince S
    1693. Proia RL
    1694. Proikas-Cezanne T
    1695. Prokisch H
    1696. Promponas VJ
    1697. Przyklenk K
    1698. Puertollano R
    1699. Pugazhenthi S
    1700. Puglielli L
    1701. Pujol A
    1702. Puyal J
    1703. Pyeon D
    1704. Qi X
    1705. Qian W-B
    1706. Qin Z-H
    1707. Qiu Y
    1708. Qu Z
    1709. Quadrilatero J
    1710. Quinn F
    1711. Raben N
    1712. Rabinowich H
    1713. Radogna F
    1714. Ragusa MJ
    1715. Rahmani M
    1716. Raina K
    1717. Ramanadham S
    1718. Ramesh R
    1719. Rami A
    1720. Randall-Demllo S
    1721. Randow F
    1722. Rao H
    1723. Rao VA
    1724. Rasmussen BB
    1725. Rasse TM
    1726. Ratovitski EA
    1727. Rautou P-E
    1728. Ray SK
    1729. Razani B
    1730. Reed BH
    1731. Reggiori F
    1732. Rehm M
    1733. Reichert AS
    1734. Rein T
    1735. Reiner DJ
    1736. Reits E
    1737. Ren J
    1738. Ren X
    1739. Renna M
    1740. Reusch JE
    1741. Revuelta JL
    1742. Reyes L
    1743. Rezaie AR
    1744. Richards RI
    1745. Richardson DR
    1746. Richetta C
    1747. Riehle MA
    1748. Rihn BH
    1749. Rikihisa Y
    1750. Riley BE
    1751. Rimbach G
    1752. Rippo MR
    1753. Ritis K
    1754. Rizzi F
    1755. Rizzo E
    1756. Roach PJ
    1757. Robbins J
    1758. Roberge M
    1759. Roca G
    1760. Roccheri MC
    1761. Rocha S
    1762. Rodrigues CM
    1763. Rodríguez CI
    1764. de Cordoba SR
    1765. Rodriguez-Muela N
    1766. Roelofs J
    1767. Rogov VV
    1768. Rohn TT
    1769. Rohrer B
    1770. Romanelli D
    1771. Romani L
    1772. Romano PS
    1773. Roncero MIG
    1774. Rosa JL
    1775. Rosello A
    1776. Rosen KV
    1777. Rosenstiel P
    1778. Rost-Roszkowska M
    1779. Roth KA
    1780. Roué G
    1781. Rouis M
    1782. Rouschop KM
    1783. Ruan DT
    1784. Ruano D
    1785. Rubinsztein DC
    1786. Rucker EB
    1787. Rudich A
    1788. Rudolf E
    1789. Rudolf R
    1790. Ruegg MA
    1791. Ruiz-Roldan C
    1792. Ruparelia AA
    1793. Rusmini P
    1794. Russ DW
    1795. Russo GL
    1796. Russo G
    1797. Russo R
    1798. Rusten TE
    1799. Ryabovol V
    1800. Ryan KM
    1801. Ryter SW
    1802. Sabatini DM
    1803. Sacher M
    1804. Sachse C
    1805. Sack MN
    1806. Sadoshima J
    1807. Saftig P
    1808. Sagi-Eisenberg R
    1809. Sahni S
    1810. Saikumar P
    1811. Saito T
    1812. Saitoh T
    1813. Sakakura K
    1814. Sakoh-Nakatogawa M
    1815. Sakuraba Y
    1816. Salazar-Roa M
    1817. Salomoni P
    1818. Saluja AK
    1819. Salvaterra PM
    1820. Salvioli R
    1821. Samali A
    1822. Sanchez AM
    1823. Sánchez-Alcázar JA
    1824. Sanchez-Prieto R
    1825. Sandri M
    1826. Sanjuan MA
    1827. Santaguida S
    1828. Santambrogio L
    1829. Santoni G
    1830. Dos Santos CN
    1831. Saran S
    1832. Sardiello M
    1833. Sargent G
    1834. Sarkar P
    1835. Sarkar S
    1836. Sarrias MR
    1837. Sarwal MM
    1838. Sasakawa C
    1839. Sasaki M
    1840. Sass M
    1841. Sato K
    1842. Sato M
    1843. Satriano J
    1844. Savaraj N
    1845. Saveljeva S
    1846. Schaefer L
    1847. Schaible UE
    1848. Scharl M
    1849. Schatzl HM
    1850. Schekman R
    1851. Scheper W
    1852. Schiavi A
    1853. Schipper HM
    1854. Schmeisser H
    1855. Schmidt J
    1856. Schmitz I
    1857. Schneider BE
    1858. Schneider EM
    1859. Schneider JL
    1860. Schon EA
    1861. Schönenberger MJ
    1862. Schönthal AH
    1863. Schorderet DF
    1864. Schröder B
    1865. Schuck S
    1866. Schulze RJ
    1867. Schwarten M
    1868. Schwarz TL
    1869. Sciarretta S
    1870. Scotto K
    1871. Scovassi AI
    1872. Screaton RA
    1873. Screen M
    1874. Seca H
    1875. Sedej S
    1876. Segatori L
    1877. Segev N
    1878. Seglen PO
    1879. Seguí-Simarro JM
    1880. Segura-Aguilar J
    1881. Seki E
    1882. Sell C
    1883. Seiliez I
    1884. Semenkovich CF
    1885. Semenza GL
    1886. Sen U
    1887. Serra AL
    1888. Serrano-Puebla A
    1889. Sesaki H
    1890. Setoguchi T
    1891. Settembre C
    1892. Shacka JJ
    1893. Shajahan-Haq AN
    1894. Shapiro IM
    1895. Sharma S
    1896. She H
    1897. Shen C-KJ
    1898. Shen C-C
    1899. Shen H-M
    1900. Shen S
    1901. Shen W
    1902. Sheng R
    1903. Sheng X
    1904. Sheng Z-H
    1905. Shepherd TG
    1906. Shi J
    1907. Shi Q
    1908. Shi Q
    1909. Shi Y
    1910. Shibutani S
    1911. Shibuya K
    1912. Shidoji Y
    1913. Shieh J-J
    1914. Shih C-M
    1915. Shimada Y
    1916. Shimizu S
    1917. Shin DW
    1918. Shinohara ML
    1919. Shintani M
    1920. Shintani T
    1921. Shioi T
    1922. Shirabe K
    1923. Shiri-Sverdlov R
    1924. Shirihai O
    1925. Shore GC
    1926. Shu C-W
    1927. Shukla D
    1928. Sibirny AA
    1929. Sica V
    1930. Sigurdson CJ
    1931. Sigurdsson EM
    1932. Sijwali PS
    1933. Sikorska B
    1934. Silveira WA
    1935. Silvente-Poirot S
    1936. Silverman GA
    1937. Simak J
    1938. Simmet T
    1939. Simon AK
    1940. Simon H-U
    1941. Simone C
    1942. Simons M
    1943. Simonsen A
    1944. Singh R
    1945. Singh SV
    1946. Singh SK
    1947. Sinha D
    1948. Sinha S
    1949. Sinicrope FA
    1950. Sirko A
    1951. Sirohi K
    1952. Sishi BJ
    1953. Sittler A
    1954. Siu PM
    1955. Sivridis E
    1956. Skwarska A
    1957. Slack R
    1958. Slaninová I
    1959. Slavov N
    1960. Smaili SS
    1961. Smalley KS
    1962. Smith DR
    1963. Soenen SJ
    1964. Soleimanpour SA
    1965. Solhaug A
    1966. Somasundaram K
    1967. Son JH
    1968. Sonawane A
    1969. Song C
    1970. Song F
    1971. Song HK
    1972. Song J-X
    1973. Song W
    1974. Soo KY
    1975. Sood AK
    1976. Soong TW
    1977. Soontornniyomkij V
    1978. Sorice M
    1979. Sotgia F
    1980. Soto-Pantoja DR
    1981. Sotthibundhu A
    1982. Sousa MJ
    1983. Spaink HP
    1984. Span PN
    1985. Spang A
    1986. Sparks JD
    1987. Speck PG
    1988. Spector SA
    1989. Spies CD
    1990. Springer W
    1991. Clair DS
    1992. Stacchiotti A
    1993. Staels B
    1994. Stang MT
    1995. Starczynowski DT
    1996. Starokadomskyy P
    1997. Steegborn C
    1998. Steele JW
    1999. Stefanis L
    2000. Steffan J
    2001. Stellrecht CM
    2002. Stenmark H
    2003. Stepkowski TM
    2004. Stern ST
    2005. Stevens C
    2006. Stockwell BR
    2007. Stoka V
    2008. Storchova Z
    2009. Stork B
    2010. Stratoulias V
    2011. Stravopodis DJ
    2012. Strnad P
    2013. Strohecker AM
    2014. Ström A-L
    2015. Stromhaug P
    2016. Stulik J
    2017. Su Y-X
    2018. Su Z
    2019. Subauste CS
    2020. Subramaniam S
    2021. Sue CM
    2022. Suh SW
    2023. Sui X
    2024. Sukseree S
    2025. Sulzer D
    2026. Sun F-L
    2027. Sun J
    2028. Sun J
    2029. Sun S-Y
    2030. Sun Y
    2031. Sun Y
    2032. Sun Y
    2033. Sundaramoorthy V
    2034. Sung J
    2035. Suzuki H
    2036. Suzuki K
    2037. Suzuki N
    2038. Suzuki T
    2039. Suzuki YJ
    2040. Swanson MS
    2041. Swanton C
    2042. Swärd K
    2043. Swarup G
    2044. Sweeney ST
    2045. Sylvester PW
    2046. Szatmari Z
    2047. Szegezdi E
    2048. Szlosarek PW
    2049. Taegtmeyer H
    2050. Tafani M
    2051. Taillebourg E
    2052. Tait SW
    2053. Takacs-Vellai K
    2054. Takahashi Y
    2055. Takáts S
    2056. Takemura G
    2057. Takigawa N
    2058. Talbot NJ
    2059. Tamagno E
    2060. Tamburini J
    2061. Tan C-P
    2062. Tan L
    2063. Tan ML
    2064. Tan M
    2065. Tan Y-J
    2066. Tanaka K
    2067. Tanaka M
    2068. Tang D
    2069. Tang D
    2070. Tang G
    2071. Tanida I
    2072. Tanji K
    2073. Tannous BA
    2074. Tapia JA
    2075. Tasset-Cuevas I
    2076. Tatar M
    2077. Tavassoly I
    2078. Tavernarakis N
    2079. Taylor A
    2080. Taylor GS
    2081. Taylor GA
    2082. Taylor JP
    2083. Taylor MJ
    2084. Tchetina EV
    2085. Tee AR
    2086. Teixeira-Clerc F
    2087. Telang S
    2088. Tencomnao T
    2089. Teng B-B
    2090. Teng R-J
    2091. Terro F
    2092. Tettamanti G
    2093. Theiss AL
    2094. Theron AE
    2095. Thomas KJ
    2096. Thomé MP
    2097. Thomes PG
    2098. Thorburn A
    2099. Thorner J
    2100. Thum T
    2101. Thumm M
    2102. Thurston TL
    2103. Tian L
    2104. Till A
    2105. Ting JP-Y
    2106. Titorenko VI
    2107. Toker L
    2108. Toldo S
    2109. Tooze SA
    2110. Topisirovic I
    2111. Torgersen ML
    2112. Torosantucci L
    2113. Torriglia A
    2114. Torrisi MR
    2115. Tournier C
    2116. Towns R
    2117. Trajkovic V
    2118. Travassos LH
    2119. Triola G
    2120. Tripathi DN
    2121. Trisciuoglio D
    2122. Troncoso R
    2123. Trougakos IP
    2124. Truttmann AC
    2125. Tsai K-J
    2126. Tschan MP
    2127. Tseng Y-H
    2128. Tsukuba T
    2129. Tsung A
    2130. Tsvetkov AS
    2131. Tu S
    2132. Tuan H-Y
    2133. Tucci M
    2134. Tumbarello DA
    2135. Turk B
    2136. Turk V
    2137. Turner RF
    2138. Tveita AA
    2139. Tyagi SC
    2140. Ubukata M
    2141. Uchiyama Y
    2142. Udelnow A
    2143. Ueno T
    2144. Umekawa M
    2145. Umemiya-Shirafuji R
    2146. Underwood BR
    2147. Ungermann C
    2148. Ureshino RP
    2149. Ushioda R
    2150. Uversky VN
    2151. Uzcátegui NL
    2152. Vaccari T
    2153. Vaccaro MI
    2154. Váchová L
    2155. Vakifahmetoglu-Norberg H
    2156. Valdor R
    2157. Valente EM
    2158. Vallette F
    2159. Valverde AM
    2160. Van den Berghe G
    2161. Van Den Bosch L
    2162. van den Brink GR
    2163. van der Goot FG
    2164. van der Klei IJ
    2165. van der Laan LJ
    2166. van Doorn WG
    2167. van Egmond M
    2168. van Golen KL
    2169. Van Kaer L
    2170. van Lookeren Campagne M
    2171. Vandenabeele P
    2172. Vandenberghe W
    2173. Vanhorebeek I
    2174. Varela-Nieto I
    2175. Vasconcelos MH
    2176. Vasko R
    2177. Vavvas DG
    2178. Vega-Naredo I
    2179. Velasco G
    2180. Velentzas AD
    2181. Velentzas PD
    2182. Vellai T
    2183. Vellenga E
    2184. Vendelbo MH
    2185. Venkatachalam K
    2186. Ventura N
    2187. Ventura S
    2188. Veras PS
    2189. Verdier M
    2190. Vertessy BG
    2191. Viale A
    2192. Vidal M
    2193. Vieira HLA
    2194. Vierstra RD
    2195. Vigneswaran N
    2196. Vij N
    2197. Vila M
    2198. Villar M
    2199. Villar VH
    2200. Villarroya J
    2201. Vindis C
    2202. Viola G
    2203. Viscomi MT
    2204. Vitale G
    2205. Vogl DT
    2206. Voitsekhovskaja OV
    2207. von Haefen C
    2208. von Schwarzenberg K
    2209. Voth DE
    2210. Vouret-Craviari V
    2211. Vuori K
    2212. Vyas JM
    2213. Waeber C
    2214. Walker CL
    2215. Walker MJ
    2216. Walter J
    2217. Wan L
    2218. Wan X
    2219. Wang B
    2220. Wang C
    2221. Wang C-Y
    2222. Wang C
    2223. Wang C
    2224. Wang C
    2225. Wang D
    2226. Wang F
    2227. Wang F
    2228. Wang G
    2229. Wang H-J
    2230. Wang H
    2231. Wang H-G
    2232. Wang H
    2233. Wang H-D
    2234. Wang J
    2235. Wang J
    2236. Wang M
    2237. Wang M-Q
    2238. Wang P-Y
    2239. Wang P
    2240. Wang RC
    2241. Wang S
    2242. Wang T-F
    2243. Wang X
    2244. Wang X-J
    2245. Wang X-W
    2246. Wang X
    2247. Wang X
    2248. Wang Y
    2249. Wang Y
    2250. Wang Y
    2251. Wang Y-J
    2252. Wang Y
    2253. Wang Y
    2254. Wang YT
    2255. Wang Y
    2256. Wang Z-N
    2257. Wappner P
    2258. Ward C
    2259. Ward DM
    2260. Warnes G
    2261. Watada H
    2262. Watanabe Y
    2263. Watase K
    2264. Weaver TE
    2265. Weekes CD
    2266. Wei J
    2267. Weide T
    2268. Weihl CC
    2269. Weindl G
    2270. Weis SN
    2271. Wen L
    2272. Wen X
    2273. Wen Y
    2274. Westermann B
    2275. Weyand CM
    2276. White AR
    2277. White E
    2278. Whitton JL
    2279. Whitworth AJ
    2280. Wiels J
    2281. Wild F
    2282. Wildenberg ME
    2283. Wileman T
    2284. Wilkinson DS
    2285. Wilkinson S
    2286. Willbold D
    2287. Williams C
    2288. Williams K
    2289. Williamson PR
    2290. Winklhofer KF
    2291. Witkin SS
    2292. Wohlgemuth SE
    2293. Wollert T
    2294. Wolvetang EJ
    2295. Wong E
    2296. Wong GW
    2297. Wong RW
    2298. Wong VKW
    2299. Woodcock EA
    2300. Wright KL
    2301. Wu C
    2302. Wu D
    2303. Wu GS
    2304. Wu J
    2305. Wu J
    2306. Wu M
    2307. Wu M
    2308. Wu S
    2309. Wu WK
    2310. Wu Y
    2311. Wu Z
    2312. Xavier CP
    2313. Xavier RJ
    2314. Xia G-X
    2315. Xia T
    2316. Xia W
    2317. Xia Y
    2318. Xiao H
    2319. Xiao J
    2320. Xiao S
    2321. Xiao W
    2322. Xie C-M
    2323. Xie Z
    2324. Xie Z
    2325. Xilouri M
    2326. Xiong Y
    2327. Xu C
    2328. Xu C
    2329. Xu F
    2330. Xu H
    2331. Xu H
    2332. Xu J
    2333. Xu J
    2334. Xu J
    2335. Xu L
    2336. Xu X
    2337. Xu Y
    2338. Xu Y
    2339. Xu Z-X
    2340. Xu Z
    2341. Xue Y
    2342. Yamada T
    2343. Yamamoto A
    2344. Yamanaka K
    2345. Yamashina S
    2346. Yamashiro S
    2347. Yan B
    2348. Yan B
    2349. Yan X
    2350. Yan Z
    2351. Yanagi Y
    2352. Yang D-S
    2353. Yang J-M
    2354. Yang L
    2355. Yang M
    2356. Yang P-M
    2357. Yang P
    2358. Yang Q
    2359. Yang W
    2360. Yang WY
    2361. Yang X
    2362. Yang Y
    2363. Yang Y
    2364. Yang Z
    2365. Yang Z
    2366. Yao M-C
    2367. Yao PJ
    2368. Yao X
    2369. Yao Z
    2370. Yao Z
    2371. Yasui LS
    2372. Ye M
    2373. Yedvobnick B
    2374. Yeganeh B
    2375. Yeh ES
    2376. Yeyati PL
    2377. Yi F
    2378. Yi L
    2379. Yin X-M
    2380. Yip CK
    2381. Yoo Y-M
    2382. Yoo YH
    2383. Yoon S-Y
    2384. Yoshida K-I
    2385. Yoshimori T
    2386. Young KH
    2387. Yu H
    2388. Yu JJ
    2389. Yu J-T
    2390. Yu J
    2391. Yu L
    2392. Yu WH
    2393. Yu X-F
    2394. Yu Z
    2395. Yuan J
    2396. Yuan Z-M
    2397. Yue BY
    2398. Yue J
    2399. Yue Z
    2400. Zacks DN
    2401. Zacksenhaus E
    2402. Zaffaroni N
    2403. Zaglia T
    2404. Zakeri Z
    2405. Zecchini V
    2406. Zeng J
    2407. Zeng M
    2408. Zeng Q
    2409. Zervos AS
    2410. Zhang DD
    2411. Zhang F
    2412. Zhang G
    2413. Zhang G-C
    2414. Zhang H
    2415. Zhang H
    2416. Zhang H
    2417. Zhang H
    2418. Zhang J
    2419. Zhang J
    2420. Zhang J
    2421. Zhang J
    2422. Zhang J-P
    2423. Zhang L
    2424. Zhang L
    2425. Zhang L
    2426. Zhang L
    2427. Zhang M-Y
    2428. Zhang X
    2429. Zhang XD
    2430. Zhang Y
    2431. Zhang Y
    2432. Zhang Y
    2433. Zhang Y
    2434. Zhang Y
    2435. Zhao M
    2436. Zhao W-L
    2437. Zhao X
    2438. Zhao YG
    2439. Zhao Y
    2440. Zhao Y
    2441. Zhao Y-X
    2442. Zhao Z
    2443. Zhao ZJ
    2444. Zheng D
    2445. Zheng X-L
    2446. Zheng X
    2447. Zhivotovsky B
    2448. Zhong Q
    2449. Zhou G-Z
    2450. Zhou G
    2451. Zhou H
    2452. Zhou S-F
    2453. Zhou X-J
    2454. Zhu H
    2455. Zhu H
    2456. Zhu W-G
    2457. Zhu W
    2458. Zhu X-F
    2459. Zhu Y
    2460. Zhuang S-M
    2461. Zhuang X
    2462. Ziparo E
    2463. Zois CE
    2464. Zoladek T
    2465. Zong W-X
    2466. Zorzano A
    2467. Zughaier SM
    (2016) Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)
    Autophagy 12:1–222.
    https://doi.org/10.1080/15548627.2015.1100356

Article and author information

Author details

  1. Raffaele Nicastro

    University of Fribourg, Department of Biology, Fribourg, Switzerland
    Contribution
    Conceptualization, Formal analysis, Investigation, Methodology, Writing – review and editing
    Contributed equally with
    Hélène Gaillard
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5420-2228

  2. Hélène Gaillard

    1. Centro Andaluz de Biología Molecular y Medicina Regenerativa - CABIMER, Consejo Superior de Investigaciones Científicas, Universidad de Sevilla, Seville, Spain
    2. Departamento de Genética, Facultad de Biología, Universidad de Sevilla, Seville, Spain
    Contribution
    Conceptualization, Formal analysis, Investigation, Visualization, Methodology, Writing – review and editing
    Contributed equally with
    Raffaele Nicastro
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5740-0641

  3. Laura Zarzuela

    Centro Andaluz de Biología Molecular y Medicina Regenerativa - CABIMER, Consejo Superior de Investigaciones Científicas, Universidad de Sevilla, Seville, Spain
    Contribution
    Investigation
    Competing interests
    No competing interests declared

  4. Marie-Pierre Péli-Gulli

    University of Fribourg, Department of Biology, Fribourg, Switzerland
    Contribution
    Conceptualization, Investigation, Methodology, Writing – review and editing
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-6908-7082

  5. Elisabet Fernández-García

    1. Centro Andaluz de Biología Molecular y Medicina Regenerativa - CABIMER, Consejo Superior de Investigaciones Científicas, Universidad de Sevilla, Seville, Spain
    2. Departamento de Genética, Facultad de Biología, Universidad de Sevilla, Seville, Spain
    Contribution
    Investigation
    Competing interests
    No competing interests declared

  6. Mercedes Tomé

    Centro Andaluz de Biología Molecular y Medicina Regenerativa - CABIMER, Consejo Superior de Investigaciones Científicas, Universidad de Sevilla, Seville, Spain
    Contribution
    Conceptualization, Investigation, Methodology
    Competing interests
    No competing interests declared

  7. Néstor García-Rodríguez

    1. Centro Andaluz de Biología Molecular y Medicina Regenerativa - CABIMER, Consejo Superior de Investigaciones Científicas, Universidad de Sevilla, Seville, Spain
    2. Departamento de Genética, Facultad de Biología, Universidad de Sevilla, Seville, Spain
    Contribution
    Conceptualization, Investigation, Methodology, Writing – review and editing
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4049-1604

  8. Raúl V Durán

    Centro Andaluz de Biología Molecular y Medicina Regenerativa - CABIMER, Consejo Superior de Investigaciones Científicas, Universidad de Sevilla, Seville, Spain
    Contribution
    Conceptualization, Resources, Data curation, Formal analysis, Supervision, Funding acquisition, Methodology, Writing – review and editing
    Competing interests
    No competing interests declared

  9. Claudio De Virgilio

    University of Fribourg, Department of Biology, Fribourg, Switzerland
    Contribution
    Conceptualization, Resources, Data curation, Formal analysis, Supervision, Funding acquisition, Methodology, Writing – original draft, Writing – review and editing
    For correspondence
    Claudio.DeVirgilio@unifr.ch
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-8826-4323

  10. Ralf Erik Wellinger

    1. Centro Andaluz de Biología Molecular y Medicina Regenerativa - CABIMER, Consejo Superior de Investigaciones Científicas, Universidad de Sevilla, Seville, Spain
    2. Departamento de Genética, Facultad de Biología, Universidad de Sevilla, Seville, Spain
    Contribution
    Conceptualization, Resources, Data curation, Formal analysis, Supervision, Funding acquisition, Investigation, Methodology, Writing – original draft, Project administration, Writing – review and editing
    For correspondence
    wellinger@us.es
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4421-6618

Funding

Universidad de Sevilla (2020/00001326)

  • Hélène Gaillard
  • Ralf Erik Wellinger

Junta de Andalucía (P20-RT-01220)

  • Ralf Erik Wellinger

European Molecular Biology Organization (STF-8685)

  • Ralf Erik Wellinger

Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (310030_166474/184671)

  • Claudio De Virgilio

Ministerio de Ciencia, Innovación y Universidades (PGC2018-096244-B-I00)

  • Raúl V Durán

Ministerio de Ciencia, Innovación y Universidades (FPU19/04914)

  • Laura Zarzuela

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Acknowledgements

We thank María Díaz de la Loza and Benjamin Pillet for scientific illustration work, and V Albanèse, E de Nadal, V Goder, KD Hirschi, C Ungermann, and E Gottlieb for plasmids, yeast strains, and cell lines. Research was funded by grants from the University of Seville (2020/00001326), Junta de Andalucía/European Union Regional Funds (P20-RT-01220) and EMBO (STF-8685) to REW; the Swiss National Science Foundation (310030_166474/184671) to CDV; the Spanish Ministry of Science, Innovation and Universities (PGC2018-096244-B-I00) to RD. The author LZ was the recipient of a predoctoral grant from the Spanish Ministry of Science, Innovation and Universities (FPU19/04914).

Copyright

© 2022, Nicastro, Gaillard et al.

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,071
    views
  • 391
    downloads
  • 24
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Raffaele Nicastro
  2. Hélène Gaillard
  3. Laura Zarzuela
  4. Marie-Pierre Péli-Gulli
  5. Elisabet Fernández-García
  6. Mercedes Tomé
  7. Néstor García-Rodríguez
  8. Raúl V Durán
  9. Claudio De Virgilio
  10. Ralf Erik Wellinger
(2022)
Manganese is a physiologically relevant TORC1 activator in yeast and mammals
eLife 11:e80497.
https://doi.org/10.7554/eLife.80497

Share this article

https://doi.org/10.7554/eLife.80497

Categories and tags

Research organisms

Further reading

    1. Biochemistry and Chemical Biology

    Stabilization of GTSE1 by cyclin D1–CDK4/6-mediated phosphorylation promotes cell proliferation with implications for cancer prognosis

    Nelson García-Vázquez, Tania J González-Robles ... Michele Pagano
    Research Article

    In healthy cells, cyclin D1 is expressed during the G1 phase of the cell cycle, where it activates CDK4 and CDK6. Its dysregulation is a well-established oncogenic driver in numerous human cancers. The cancer-related function of cyclin D1 has been primarily studied by focusing on the phosphorylation of the retinoblastoma (RB) gene product. Here, using an integrative approach combining bioinformatic analyses and biochemical experiments, we show that GTSE1 (G-Two and S phases expressed protein 1), a protein positively regulating cell cycle progression, is a previously unrecognized substrate of cyclin D1–CDK4/6 in tumor cells overexpressing cyclin D1 during G1 and subsequent phases. The phosphorylation of GTSE1 mediated by cyclin D1–CDK4/6 inhibits GTSE1 degradation, leading to high levels of GTSE1 across all cell cycle phases. Functionally, the phosphorylation of GTSE1 promotes cellular proliferation and is associated with poor prognosis within a pan-cancer cohort. Our findings provide insights into cyclin D1’s role in cell cycle control and oncogenesis beyond RB phosphorylation.

    1. Biochemistry and Chemical Biology
    2. Microbiology and Infectious Disease

    Teichoic acids in the periplasm and cell envelope of Streptococcus pneumoniae

    Mai Nguyen, Elda Bauda ... Cecile Morlot
    Research Article

    Teichoic acids (TA) are linear phospho-saccharidic polymers and important constituents of the cell envelope of Gram-positive bacteria, either bound to the peptidoglycan as wall teichoic acids (WTA) or to the membrane as lipoteichoic acids (LTA). The composition of TA varies greatly but the presence of both WTA and LTA is highly conserved, hinting at an underlying fundamental function that is distinct from their specific roles in diverse organisms. We report the observation of a periplasmic space in Streptococcus pneumoniae by cryo-electron microscopy of vitreous sections. The thickness and appearance of this region change upon deletion of genes involved in the attachment of TA, supporting their role in the maintenance of a periplasmic space in Gram-positive bacteria as a possible universal function. Consequences of these mutations were further examined by super-resolved microscopy, following metabolic labeling and fluorophore coupling by click chemistry. This novel labeling method also enabled in-gel analysis of cell fractions. With this approach, we were able to titrate the actual amount of TA per cell and to determine the ratio of WTA to LTA. In addition, we followed the change of TA length during growth phases, and discovered that a mutant devoid of LTA accumulates the membrane-bound polymerized TA precursor.

    1. Biochemistry and Chemical Biology
    2. Computational and Systems Biology

    In silico screening by AlphaFold2 program revealed the potential binding partners of nuage-localizing proteins and piRNA-related proteins

    Shinichi Kawaguchi, Xin Xu ... Toshie Kai
    Research Article

    Protein–protein interactions are fundamental to understanding the molecular functions and regulation of proteins. Despite the availability of extensive databases, many interactions remain uncharacterized due to the labor-intensive nature of experimental validation. In this study, we utilized the AlphaFold2 program to predict interactions among proteins localized in the nuage, a germline-specific non-membrane organelle essential for piRNA biogenesis in Drosophila. We screened 20 nuage proteins for 1:1 interactions and predicted dimer structures. Among these, five represented novel interaction candidates. Three pairs, including Spn-E_Squ, were verified by co-immunoprecipitation. Disruption of the salt bridges at the Spn-E_Squ interface confirmed their functional importance, underscoring the predictive model’s accuracy. We extended our analysis to include interactions between three representative nuage components—Vas, Squ, and Tej—and approximately 430 oogenesis-related proteins. Co-immunoprecipitation verified interactions for three pairs: Mei-W68_Squ, CSN3_Squ, and Pka-C1_Tej. Furthermore, we screened the majority of Drosophila proteins (~12,000) for potential interaction with the Piwi protein, a central player in the piRNA pathway, identifying 164 pairs as potential binding partners. This in silico approach not only efficiently identifies potential interaction partners but also significantly bridges the gap by facilitating the integration of bioinformatics and experimental biology.